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The Engineering of Chinese Hamster Ovary Cells to Achieve More Efficient Gene 




This dissertation addresses the issue of the long development times of obtaining Chinese 
hamster ovary (CHO) cells capable of producing high quantities of therapeutic proteins.  
It addresses the specific time bottlenecks associated with developing high producing 
CHO cell lines and reviews various methods that are employed to alleviate these 
bottlenecks.  The specific time consuming process of gene amplification is the focus of 
this work.  Gene amplification is the process of selecting CHO cells which have been 
genetically modified to contain many copies of a therapeutic transgene, and therefore has 
the ability to produce a high amount of therapeutic protein.  Two separate projects are 
described which decrease the time necessary to obtain a high producing cell.  The first 
project describes a novel process developed which can measure and quantify the 
amplification rate of a transgene in CHO cells.  This process was used to successfully 
isolate a CHO cell clone with the capability of amplifying a transgene targeted to a 
specific location in the genome and thus produce higher quantities of protein in a shorter 
time period.  Site-specific recombination (SSR) technology was utilized to target the 
transgene to this location which was deemed capable of amplifying a transgene at a high 
rate.  The second project also utilizes SSR technology to integrate many copies of a 
transgene into many recombination sites in the CHO genome.  A cell line containing 
several thousand integration sites was isolated, however only about twenty of these sites 
successfully integrated a transgene after optimizing cell transfection conditions.  Efforts 
towards engineering an improved recombinase for this purpose has led to the result that 
  
DNA sequences flanking recombination sites have the ability to greatly improve this 
integration process.  Potential future experiments are described which may isolate such 
sequences and ultimately increase the number of transgenes integrated into the CHO cell 
genome.  Overall, these improvements to CHO cells have the ability to ultimately isolate 
a higher producing cell line faster, thus decreasing the time to get a potential drug 
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Biological molecules have emerged over the past decade as effective treatments for 
various conditions.  This has led to biotechnology and pharmaceutical companies shifting 
more efforts toward the research and development of such molecules as opposed to 
synthetic small molecule based drugs.  The demand for biologics has increased rapidly 
over the past decade and has nearly doubled in the last five years in terms of worldwide 
sales.  Although worldwide sales of both types of drugs have increased, the increase in 
demand for biologics is much larger relative to total worldwide sales and this trend is 
expected to continue (Lehman, 2007).    The majority of these molecules are recombinant 
proteins such as antibodies, hormones and enzymes with very specific cellular functions.  
 
A subdivision of these biologics whose demand is increasing at a rapid pace constitutes 
monoclonal antibodies (Mab’s).  Mab’s are currently the best selling and highest growing 
class of biologics with a market of about 18.5 billion dollars and a growth rate of about 
10% as of 2010 (Aggarwal, 2011).    Mab’s are engineered biomolecules which 
specifically recognize and bind antigens or receptors in/on various cells (mimicking 
antibodies naturally produced in the body) to perform specific functions in treating 
varying conditions.  This class of molecules is particularly effective in treating various 
types of cancer.  Mab’s have been engineered to bind ligands on certain cancerous cells 
making them more visible to the immune system for their destruction.  Mab’s have the 
ability to trigger both complement-dependent cytotoxicity (CDC) and antibody-
dependent cellular cytotoxicity (ADCC) upon binding the surface of a cancer cell.  Other 
proteins bind the membrane bound Mab which recruits the membrane attack complex 
(MAC) for cellular destruction.  Receptors on immune effector cells may bind the Fc 
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region of the bound Mab which triggers destruction of the cancer cell by that particular 
effector (Sawada et al., 2011).  The binding of Mab’s may also destroy cancer cells using 
other mechanisms upon binding antigens associated with tumors.   For example, the drug 
rituximab (Rituxan) is engineered to specifically bind the protein CD20 on the surface of 
B cells.  This allows the immune system to destroy cancerous B cells associated with 
certain lymphomas more effectively (Wood, 2001).  Mab’s have also been engineered to 
bind to receptors on cancer cells that block certain growth signals.  This inhibition 
prevents cancer cells from dividing.  One drug currently on the market that acts in this 
manner is cetuximab (Erbitux) which binds receptors on cancerous cells that block the 
binding and action of epidermal growth factor (Mendelsohn and Baselga, 2000).  This 
drug is currently used to treat colon and head and neck cancer.  Another mode of action 
of Mab’s is inhibiting the formation of blood vessels which provide nutrients to 
cancerous cells.  The drug bevacizumab (Avastin) binds to vascular endothelial growth 
factor (VEGF) which inhibits a cancer cell’s ability to initiate the formation of new blood 
vessels (Ranieri et al., 2006).  Mab’s may also be combined with other molecules for the 
direct targeting of those molecules to cancer cells through specific binding of the Mab to 
tumor antigens.  Mab’s have been linked to radioactive particles as a means of delivering 
radiation more specifically to cancer cells.  Ibritumomab (Zevalin) is used to treat non-
Hodgkin’s lymphoma by specifically binding receptors on cancerous blood cells and 
delivering low levels of radiation (Lin and Iagaru, 2010).  Another example of combining 
Mab’s with other molecules for treatment is the process of antibody-directed enzyme 
prodrug therapy (ADEPT).  This method links an enzyme to a Mab which specifically 
binds cancer cells.  After this occurs a prodrug is administered to the patient that will 
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only be converted to its active form by the enzyme on the cancer cells bound by the Mab 
(Syrigos and Epenetos, 1999).  This is an effective way of targeting another drug to 
cancer cells through the specificity of Mab binding.   
 
Initially, murine Mab’s were isolated using hybridoma technology which involves fusing 
an antibody producing cell with a myeloma cell.  These Mab’s often caused problems 
because the human immune system would reject the molecule since it was produced in a 
mouse (Stern and Herrmann, 2005).  This has led to the development of chimeric 
antibodies which contain murine variable regions (for antigen binding) connected to 
human constant regions.  This has significantly reduced immunogenicity in humans.  
Humanized Mab’s have also been developed by substituting portions of the murine 
variable domain onto a fully human antibody (Presta et al., 1993).  Fully human 
antibodies have also been developed by introducing human immunoglobulin genes into 
transgenic mice for their production after vaccination of the mice (Hudson and Souriau, 
2003).  Each of these types of antibodies is represented in the current portfolio of Mab’s 
on the market. 
 
The co-emergence of recombinant DNA technology has allowed for development of a 
successful platform for the manufacture of Mab’s.   Using recombinant DNA technology 
allows for the modification of immunoglobulin genes to discover and test large numbers 
of Mab’s for their efficacy in binding certain targets associated with many disease types.  
The current platform for producing these molecules involves the use of host cells 
transfected with Mab genes for expression, translation, and secretion of the molecule.   
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The complexity of Mab’s requires that they be produced in mammalian cells as opposed 
to bacterial cell lines.  Mammalian lines allow proper folding and glycosylation, 
necessary to the activity of these proteins.  This current platform acts as a time bottleneck 
when considering the number of Mab candidates that need to be produced and tested for 
pre-clinical study.  Furthermore, unlike other recombinant proteins previously 
manufactured such as erythropoietin and tissue plasminogen activator (tPA), therapeutic 
Mab’s are needed in relatively large amounts per dose which makes meeting the ever 
increasing demand for these molecules even more challenging.  Although there has been 
considerable work done to improve processes for the development and manufacture of 
such molecules, the pace of increasing demand seems to be surpassing current methods.   
 
The ever increasing demand for Mab’s has made it necessary to rapidly produce many 
candidates for testing in order to quickly get these drugs to market.  Even for preclinical 
studies, significant amounts of the drug candidate are needed.  The process of 
transfecting Mab genes into host cells and isolating productive transfectants for 
producing these molecules is a major time bottleneck.  Since these molecules are 
produced as transfected transgenes into a host cell, there is a limitation on production 
based on how well the Mab gene is expressed, translated, and ultimately secreted into the 
cell culture medium.  Each of these steps may act as a bottleneck to producing more Mab; 
however the main focus of this thesis is to improve the amount of Mab gene expression.  
There have already been numerous studies which have improved expression of the Mab 
gene by modifying the expression vector with enhancing sequences, insulators, and 
superior promoters.  Since these vector sequences are already somewhat established, our 
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work focuses on achieving a cell line with many copies of this transgene in a shorter 
period of time; thus increasing expression and production of the Mab per cell.  The 
current protocol for achieving high copy numbers of a Mab transgene in the host cell is a 
very time consuming process and takes about 6 months.  The goal of this thesis is to 
develop a method for shortening this process, thus ultimately decreasing the time in 
which a Mab candidate can reach the market.   
 
In Chapter 2 the current production method used to produce therapeutic proteins such as 
Mab’s in the Chinese hamster ovary (CHO) cell is discussed.  This cell line is the most 
common host for various reasons described in this chapter.  The various methods of 
transgene transfection and establishment of cell lines with many copies of that transgene 
through a process known as gene amplification are also discussed in detail.  Various ways 
for making the production process more efficient are reviewed in detail including 
improved selection of high producing clones, modified gene amplification protocols, 
modifying the expression vector for improved expression, and utilizing site-specific 
recombination (SSR) technology to target the transgene to favorable genomic locations.   
 
Chapter 3 focuses on alleviating the time bottleneck associated with isolating CHO cells 
with many copies of the Mab transgene through the gene amplification process.  Gene 
amplification refers to the random duplication of a portion of the CHO genome during 
cell division.  Isolation of a cell that has undergone this random process many times at 
the locus containing the Mab gene is possible using a specific selection process described 
in more detail in Chapters 2, 3 and 4.  In Chapter 3 we develop a method for isolating 
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clones of CHO cells that have the ability to amplify DNA at a specific genomic location 
at a high rate, thus decreasing the time needed to isolate a high Mab gene copy number 
clone.  Our method utilizes fluctuation analysis developed by Luria and Delbruck to 
measure amplification rates in 100 CHO clones.  Once high rate clones are identified and 
isolated, we target a transgene for the assayable protein secreted embryonic alkaline 
phosphatase (SEAP) to those locations deemed highly amplifiable using SSR technology.  
We specifically use the φC31 recombination system which is explained in detail in 
Chapter 2.  We confirm that using our most highly amplifiable clone, we can improve the 
reliability of achieving a high copy number cell line. 
 
Chapter 4 focuses on the theory associated with the analysis employed in Chapter 3.  The 
derivation of the equations used for determining gene amplification rates are explained in 
detail.  Parallels are made between Luria and Delbruck’s use of these methods in 
determining bacterial mutation rates and our adaptation to calculate gene amplification 
rates in CHO cells.   
 
Chapter 5 also focuses on alleviating the time bottleneck associated with isolating CHO 
cells with many copies of the Mab transgene.   Unlike the work described in Chapter 3, 
we aim to develop a method for integrating many copies of a transgene into a host CHO 
cell without the need for a lengthy gene amplification protocol.  Whereas in Chapter 3 we 
discuss our successful isolation of clone with the ability to undergo the amplification 
process faster, in Chapter 5 we describe our work towards a single experimental protocol 
utilizing site-specific recombination technology to quickly isolate a high copy number 
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cell line.  We used two different SSR methods to achieve this goal; the cre/lox system 
and the aforementioned φC31 recombination system.  We describe various ways to 
improve the integration of transgenes into many host genomic locations since SSR is 
inherently inefficient.  These methods include increasing the number of sites for SSR, 
alternative DNA transfection techniques, increasing incoming DNA concentration using a 
viral replication scheme, and improving the efficacy of the φC31 enzyme to promote 
more efficient DNA recombination into a large number of genomic locations.   
 
Chapter 6 details our overall conclusions from two separate yet connected efforts; both of 
which aim to decrease the development time of a CHO cell containing many copies of a 
transgene leading to a high protein production per cell.  The application is specifically 
geared toward the quick production of Mab candidates for preclinical and clinical study 
for the treatment of cancer and other diseases.  We summarize our main conclusion for 
Chapter 3 which is the isolation of a CHO clone capable of fast transgene amplification 
and the development of a method which can be employed to isolate a fast amplifying cell 
line of a different lineage.  We also draw conclusions based on the results described in 
Chapter 5 which implies that modifying the φC31 enzyme and the DNA recognition 
sequences it binds may be necessary to develop a way which completely abrogates the 
need for lengthy gene amplification.  We describe future experiments which can be 
conducted to this extent.    Finally we describe the overall application to the current 
methods employed by the pharmaceutical industry to isolate high producing cell lines and 
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Demand is increasing for therapeutic biopharmaceuticals such as monoclonal antibodies.  
Achieving maximum production of these recombinant proteins under developmental time 
constraints has been a recent focus of study.  The majority of these drugs are currently 
produced in altered Chinese hamster ovary (CHO) cells due to the high viability and the 
high densities achieved by these cells in suspension cultures.  However, shortening the 
process of developing and isolating high-producing cell lines remains a challenge.  This 
article focuses on current expression systems used to produce biopharmaceuticals in 
CHO cells and current methods being investigated to produce biopharmaceuticals more 
efficiently.  The methods discussed include modified gene amplification methods, 
modifying vectors to improve expression of the therapeutic gene and improving the 
method of selecting for high producing cells.  Recent developments that use gene 
targeting as a method for increasing production are discussed. 
 











The high specificity of protein-based drugs such as monoclonal antibodies 
(MAbs) has made them particularly effective for the treatment of various diseases 
including several types of cancer.  This realization has shifted the efforts of 
pharmaceutical companies toward the manufacture of more therapeutics that are protein 
based (Pearson, 2007).  The production of such therapeutics requires the use of 
mammalian cell lines and not yeast or bacteria, since mammalian cells allow the folding 
and glycosylation necessary for the activity of these drugs.  A majority of these proteins 
are currently produced using Chinese hamster ovary (CHO) cells, for several reasons.  
First, this cell line, similar to other mammalian cells used for production, has the ability 
to modify its protein products with glycosylation patterns similar to those in humans 
(Jayapal et al., 2007).  Second, these cells have the ability to grow to high densities in 
bioreactors.  Third, they  pose a low risk for the transmission of human viruses (Wiebe, 
1989).  Fourth, this cell line is known to have a very unstable genome relative to other 
candidate cell lines considered for production, making them good candidates for gene 
amplification and other genetic manipulations.  Fifth, CHO cells, similar to other cell 
candidates, can be easily transfected with gene vectors that are expressible to produce 
therapeutic proteins of choice.   Finally, industrial CHO production processes involving 
gene transfection and selection are well characterized.    Contravening these many 
advantages, the quick development of cell lines which maximize protein production 
remains a challenge.  Other cells currently being used for biopharmaceutical production 
include NS0 (mouse myeloma-derived), BHK, HEK-293, and PER-C6 (human retina-
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derived) (Wurm, 2004).  CHO cells are currently the most widely used cells for 
production and they will be the main focus of this review. 
 




A majority of platforms utilize mutant strains of CHO cells that have both alleles 
of the dihydrofolate reductase (dhfr) gene mutated (Urlaub and Chasin, 1980) or deleted 
(Urlaub et al., 1983).  DHFR catalyzes the conversion of folic acid to tetrahydrofolate 
and is necessary for biosynthetic pathways that produce glycine, purines, and thymidylic 
acid.  These auxotrophic cell lines require growth medium containing glycine, a source of 
purines such as hypoxanthine, and thymidine (GHT) for their survival.  A typical scheme 
for production of a protein-based drug begins with co-transfection of the gene for the 
protein of choice and a dhfr minigene.  The gene for the protein of choice and the dhfr 
minigene may be present on the same vector or two separate vectors as both are 
integrated at the same location regardless (Chen and Chasin, 1998).  DHFR is used as a 
selection marker for cells that have successfully integrated the vector.  Thus, CHO cells 
that have successfully integrated the expression vector for the drug of interest will have 
also integrated the dhfr gene, and will survive in medium deficient in GHT.  The 
resulting pool of cells will have the gene integrated into their genomes at various 
locations, where each may exhibit different levels of expression as determined by the 
surrounding sequence into which the vector has been randomly integrated.  Thus, the 
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ability to isolate mutants lacking DHFR allows easy selection of stable clones.  This 
selection of surviving clones has no effect on productivity of the gene of choice since 
only a low level of dhfr expression is required for survival. 
An alternative to generating stable cell lines for recombinant protein production is 
to perform transient transfection.  Transient expression of the therapeutic protein gene is 
capable of producing up to 1 g/L of product within a span of about a week (Backliwal et 
al., 2008a; Morrow, 2008).  Although this is lower than the maximum yields achievable 
with stably transfected cell lines, the short time required to harvest protein makes this an 
attractive option (Wurm, 2004).  Advantages of transient transfection include simpler 
expression vectors since no selective marker is used, a short time frame for production, 
applicability to a wide range of cell lines, and genetic stability of cells due to the short 
production time frame (Wurm and Bernard, 1999).  In many scenarios these advantages 
can outweigh the lower yields of transient transfection compared to permanent 
transfection and the repeated requirement for producing large amounts of plasmid DNA 
for each run.   
Permanent cell lines have the advantage of utilizing the highest expressing clones 
from a pooled population, allowing optimization of culture conditions for those particular 
clones to provide the highest yield, and the availability of a standard workhorse for 
repeated use. This process may take several months, but it continues to be the most 







At this point in the development phase, a method is often used to obtain cell lines 
that have a high copy number of the integrated transgene due to gene amplification, a low 
frequency event which occurs during cell division in CHO cells.  Among the isolated 
stable clones are a small number that have a high copy number of the integrated 
transgene.  A step frequently used to increase expression of a transfected gene exploits 
dhfr gene amplification.  Transfected cells carrying both the dhfr minigene and a gene for 
a protein of interest are exposed to a low concentration of methotrexate (MTX).  
Methotrexate is a specific inhibitor of DHFR and cells that acquire resistance  are usually 
found to have undergone dhfr gene amplification at the site of the integrated dhfr vector 
(Nunberg, 1978).  The result will be cells with an increased copy number for both dhfr 
and the protein of interest, since these are usually integrated together even when 
introduced on separate plasmids (Chen and Chasin, 1998).  The majority of cells, which 
have not undergone amplification, will be unable to survive the inhibitory action of MTX.  
This procedure is repeated using gradually increasing concentrations of MTX in order to 
increase the selection pressure until only cells with very high gene copy numbers prevail.  
The result is a pool of cells with varying integration sites and increased gene copy 
numbers.  MTX selection of amplificants is a major bottleneck in the production of 
biopharmaceuticals since many rounds are required to obtain cells with high gene copy 
numbers, a process that typically takes several months. Moreover, increasing MTX 
concentrations are only capable of selecting high copy number clones to a certain extent.  
At a certain concentration, higher MTX concentrations fail to yield clones with 
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increasing copy number.  This time bottleneck prevents quick production of a protein 
product for pre-clinical evaluation.  The saturation effect of using MTX to select for 




 A similar amplification protocol exists using glutamine synthetase (GS) mediated 
gene amplification.  GS-mediated amplification utilizes the GS enzyme, which catalyzes 
the synthesis of glutamine from glutamate and ammonia (Bebbington et al., 1992).  This 
system typically requires the use of a cell line other then CHO, specifically the NS0 
murine myeloma cell type.  Analogous to the dhfr-deficient CHO cells, NS0 cells are 
auxotrophic for glutamine and can be selected for in glutamine free medium (Jun et al., 
2006).  Utilizing this system in CHO cells requires the concurrent addition of methionine 
sulfoximine (MSX), a specific inhibitor of GS at a low level (20µM) for the selection of 
transfectants since CHO cells possess endogenous glutamine synthetase (Brown et al., 
1992).  Through the use of MSX during the selection of transfectants, a mutant cell line is 
not required for transfection unlike the dhfr selection system.  Another advantage of this 
system is that isolated transfectants using the GS system have higher production levels 
before gene amplification when compared to transfectants using the dhfr system (Cockett 
et al., 1990).  Despite these advantages over the dhfr system, there is data to suggest that 
production is unstable using GS-mediated amplification.    High-producing subclones of 
recombinant CHO cells producing humanized antibody isolated at various MSX 
concentrations showed a significant decrease in production over the first six passages 
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(Jun et al., 2006).  Moreover, cytogenetic studies revealed unstable chromosome structure 
that may contribute to production instability (Jun et al., 2006).  Due to these drawbacks, 
the dhfr system continues to be the most popular within the pharmaceutical industry 
despite its lengthy gene amplification regimen.  For this reason, the dhfr system will be 




A second bottleneck in the isolation of a high-producing cell line is the selection 
of the clones from an amplified pool of cells that exhibit the best productivity and growth 
rate, properties that depend upon but are not wholly determined by copy number.  
Standard methods involve isolating individual colonies through limiting dilution (Puck 
and Marcus, 1955) or cloning cylinders (Davis, 2002).  Each clone is then evaluated for 
both its growth rate and its rate of productivity of the protein of interest.  Both processes 
are very time consuming and thus hinder the development of new biopharmaceuticals. 
Two different strategies are used for the selection of high-producing clones.  The 
first involves isolating individual clones from the first level of MTX selection, subjecting 
each clone to a higher level of MTX, again isolating single clones, and so on for each 
level of selection. Subcloning can also be carried out to optimize homogeneity  (Kim et 
al., 1998).  The second strategy involves pooling clones at each stage of the MTX 
selection and isolating individual clones only from the final MTX resistant pool.  A study 
was performed to compare the efficacy of these two strategies.  Jun et. al. compared the 
antibody productivity of 30 parental clones to 10 parental cell pools after subjecting both 
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to the MTX amplification procedure.  High-producing clones were isolated from the cell 
pools within 15 weeks at an antibody titer of approximately 5 µg/ml.  High producers 
were isolated from the 30 parental clones in about 17 weeks with the highest subclone 
achieving a titer of approximately 17 ug/ml (Jun et al., 2005).  The individual clone 
strategy proved to be labor intensive and more time consuming due to an extra cloning 
step.  This protocol was not improved by including MTX in the initial selection of 
transfectants.  The cell pool strategy was less labor intensive; however the highest 
producer was about one third as productive as the highest producer isolated using the 
individual clone strategy.  The disparity could be due to high-producing clones within  
each pool displaying lower growth rates and being overtaken by lower producing clones 
(Imanaka and Aiba, 1981).  Despite being more labor intensive, the method of selection 
and amplification using individual clones may be more efficient in the end (Jun et al., 
2005).   
Even after isolation of the most productive clones, their performances must be 
evaluated in various types of media and in scaled-up scenarios for production in larger 
vessels.  Recent effort has been focused on optimizing media formulations for the growth 
of these production cell lines.  The optimum formulation for one high-producing clone 
may not be effective in achieving high production rates from another (Gerber et al., 2008).  
The need to find an optimum medium that may be specific to each clone accentuates the 
necessity of efficiently isolating high-producing clones upstream of the process of 
medium selection.   
A number of host cell improvements have also been implemented for maximizing 
production through genetic engineering.  Maintaining viability and favorable growth 
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characteristics remains a key goal in cell line development.  It is common that isolated 
clones with high specific productivity have low growth rates (Arden et al., 2004).  
Furthermore, cell apoptosis during production acts to decrease viability.  To address these 
problems, cell cycle control genes (cyclins), growth factor genes, and anti-apoptotic 
genes have been incorporated into cell lines for enhanced viability and optimal growth 
rate (Arden et al., 2004).  In addition to high production, achieving product quality and 
efficacy is also important.  This often requires the improvement of post-translational 
protein modifications.  Protein glycosylation is perhaps the most prominent of these 
modifications. Examples of genetically engineering the gylcosylation pattern  in CHO 
cells include the overexpression of  N-acetylglucosaminyltransferase-III (Umana et al., 
1999). and the knockout of α-1,6-fucosyltransferase to modify the resulting glycoform for 
improved mediation of antibody dependent cellular toxicity. 
 
Improved selection technologies 
 
Increasing demand for biopharmaceuticals as well as the problems cited above has 
triggered the development of high-throughput methods for clone selection.  One 
technology utilized for this process is flow cytometry, which allows the screening of 
large numbers of transfectants (Browne and Al-Rubeai, 2007).  This method has been 
implemented by immobilizing a scaffold on the surface of cells with a high affinity for 
the recombinant protein (Holmes and Al-Rubeai, 1999).  Using a fluorescent ligand, the 
cells with the highest fluorescence can be isolated using a fluorescence-activated cell 
sorter (FACS).  The isolated high producers can then be cloned using the methods 
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described above or by FACS sorting into 96-well dishes and evaluated for productivity 
and growth rate.  Another fluorescence-based selection platform that involves cell sorting 
utilizes fluorescently labeled MTX.  Cells that are expressing high levels of DHFR can be 
made highly fluorescent by the addition of fluorescently labeled MTX that is specifically 
bound to the DHFR enzyme (Yoshikawa, 2001).  These high DHFR producers are then 
isolated by flow cytometry on the assumption that they will be high producers of the 
protein of interest.  A more recent method uses vectors with dual fluorescent labels that 
assess production of each chain of an antibody product.  In particular, the reporters eYFP 
and eGFP are used to evaluate the production of the light chain and heavy chain of an 
antibody product, respectively. These reporter proteins are translated from an internal 
ribosome entry site (IRES) placed downstream of the coding regions of the proteins of 
interest. This method offers a single-step approach for isolating high producers and is a 
more accurate determinant of MAb productivity since the expression of both antibody 
chains is evaluated (Sleiman, 2007). 
Another FACS-based method utilizes the Single Cell Secretion Assay (Borth et al., 2000) 
to measure production rates of individual cells by retaining secreted products on the cell 
surface after binding an externally applied antibody to the cells (Manz et al., 1995).  This 
method was utilized to isolate high producers that also exhibited high production 
independent of growth rate and increased cell line stability.  Sorting was performed on 
cells grown under conditions of cell density dependent growth inhibition.  Cells were also 
cultivated without selection pressure for 180 days to isolate cells with increased stability.  
Using this assay with these specific conditions allowed for selection of desired variants 
after one sort and has the potential to play a key role in cell line optimization (Bohm et al., 
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2004).  FACS-based methods utilizing detection of a reporter protein have also been 
investigated.  One study uses the gene for cell surface protein CD20 linked to the gene 
for the therapeutic protein through an IRES.  Since the CD20 is co-expressed with the 
therapeutic protein, expression is detected using a fluorescent anti-CD20 antibody.  This 
is advantageous since an antibody specific for the therapeutic protein is not required.  
This method is capable of  analyzing expression of over 1000 clones per day (DeMaria et 
al., 2007). 
 Other methods have been developed that do not require the addition of an 
immobilization scaffold on the surface of cells.  One such method takes advantage of the 
transient association of any secreted protein on the surface of cells.  Since this occurs 
downstream of secretory bottlenecks, it is an accurate determinant of secreted protein 
from the cell (Brezinsky et al., 2003) .  Cold temperatures were used for this assay since 
endocytosis of protein product aggregates is slowed at low temperatures.  Using 
fluorescently tagged antibodies that bind to the secreted product at low temperature and 
cell sorting, specific productivity of murine MAb AQC2 directed against human alpha 1 
beta 1 integrin was increased up to 120-fold when used in conjunction with MTX 
amplification (Brezinsky et al., 2003).  This cold capture assay has been demonstrated to 
be a robust process with over 20 secreted proteins tested for improved specific 
productivity (Brezinsky et al., 2003).  Pichler et. al. performed a temperature dependency 
and time course study of this assay and determined that the fluorescent signal is stable for 
up to 24 h at temperatures ranging from 4 to 20oC (Pichler et al., 2009).   
   
 22
 Automated systems (LEAP, Laser Enabled Analysis and Processing) have been 
developed that are capable of identifying high-producing adherent cells or colonies based 
on labeling the localized secreted product with fluorescent antibodies (Koller, 2004; 
Hanania, 2005).  One method can be utilized for human and humanized IgG production.  
Cells are grown on a proprietary matrix that specifically retains secreted IgG.   Next, a 
fluorescent-conjugated anti-IgG detection reagent is added to the culture and binds to the 
secreted IgG; cells are also generally labeled with a viable cell dye.  Upon imaging, an 
algorithm calculates the intensity surrounding each cell and targets lasers to destroy low-
producing cells, sparing high producers which can then proliferate without competition 
(Cresswell et al., 2009).   The LEAP method is depicted in Fig. 1.  Another system uses a 
robotic colony picker to isolate highly fluorescent colonies grown in a semi-solid medium 









Figure 1. Laser-enabled analysis and processing of IgG secreting cells.   
IgG molecules that are secreted are captured by binding to a proprietary matrix on which 
the cells are growing. Accumulated secreted products are then detected using a 
fluorescently labeled anti-IgG.  Low and non-producing cells are automatically laser 
ablated but the cells passing a threshold of fluorescence are spared and allowed to grow 
into colonies.  
 
Although these methods of screening high producers in a high-throughput manner 
decrease development time significantly, the technology is expensive and is often 
particular to each cell line.  Specific antibodies directed against the protein drugs being 
produced may be difficult to obtain (Browne and Al-Rubeai, 2007).   
 
Improving production using modified amplification methods 
 
The recently developed strategies to be discussed below differ from the selection 
technologies discussed above in that they modify gene vectors to increase the average 
production per cell a priori as opposed to developing technology for high-throughput 
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selection of clones from a large pool of cells a posteriori.  These methods utilize vector 
engineering techniques and gene recombination reactions to obtain high levels of protein 
production.  These methods aim to decrease the development time associated with 
standard MTX amplification without sacrificing production levels per cell.  They also 
aim to achieve acceptable product yields without performing MTX amplification.  Finally, 
they aim to decrease development time while minimizing additional development costs.  
Although the ideal strategy addresses all these goals, any method that achieves one of 
them can be a general tool for the development of many different biopharmaceuticals in a 
limited amount of time.  
 
Traditional vectors used to clone the gene that codes for a therapeutic protein product 
often contain elements to enhance transcription of the gene.  The gene is usually under 
control of a strong mammalian promoter such as the cytomegalovirus (CMV) promoter.  
The following three novel techniques engineer the dhfr vector to allow more stringent 
selection conditions by increasing the effectiveness of MTX amplification.  One method 
adds a second marker for amplification and the other two methods weaken the dhfr 
marker so as to enhance its range of amplification. 
 
Dual marker amplification 
 
One method to increase the power of MTX amplification depends upon another 
amplifiable marker analogous to dhfr that allows extra amplification steps after the ability 
of MTX to select amplificants is exhausted.   
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 A typical approach to the use of more than one marker utilizes dicistronic vectors 
for the isolation of clones with enhanced production capacity for thyroid-stimulating 
hormone (TSH)  (Peroni et al., 2002).  The vector contains one functional unit of the 
hormone and one unit to be used in the selection process.   A standard protocol for the 
production of this drug involves the co-transfection of a therapeutic protein gene and a 
dhfr gene either on two different plasmids or on the same plasmid, followed by MTX 
amplification. In this study, vectors were constructed that contained separate amplifiable 
marker genes.  One vector contained the gene for the α subunit of TSH and dhfr and the 
other vector contained a gene for the β subunit and adenosine deaminase (ADA).  Co-
transfecting these two vectors allowed two sequential selections, first via MTX resistance 
and then via deoxycoformycin (dCF) resistance based on the amplification of the ADA 
gene.  The dCF drug is a specific inhibitor of ADA. (Kaufman et al., 1986)  Using MTX 
amplification alone, a secretion level of 7.2 +/- 1.3 µg/106 cells per day of TSH was 
reported. Subsequent selection with dCF  yielded a high-producing clone with a secretion 
level of 17.8 +/- 7.6 µg/106 cells/day (Peroni et al., 2002).  The dual amplification 
strategy yielded a 2-3 fold increase in TSH production in contrast to the yield of a single 
amplification step.  However, this strategy requires a second selection protocol.  A higher 
level of protein production came at the cost of a longer development time. 
This protocol has also been applied to production of IgG (Fouser et al., 1992).  
The light chain gene was linked to the dhfr gene and the heavy chain was linked to the 
ADA gene.  CHO cell lines that underwent dual amplification using these two markers 
produced a chimeric anti-ganglioside GD2 mAb at 80-110 µg/106 cells/day (Trill et al., 
1995).   
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Improving MTX amplification through weakening of the dhfr marker 
 
The standard MTX amplification protocol can be modified to obtain higher 
producers by weakening the dhfr selection marker.  Since gene amplification occurs over 
a DNA sequence that includes the dhfr gene and the therapeutic protein gene, their copy 
numbers both increase equally through each round of amplification.  If dhfr activity is 
weakened, cells resistant to a specific dose of MTX will require a greater number of dhfr 
genes.  Thus the amplification can be expanded to yield greater copy numbers for both 
the marker and production genes.  
 
DHFR expression via incomplete splicing 
 
A  different amplification method used an engineered vector for the increased 
production of chimeric antibodies from CHO cells (Xiong et al., 2005).  The vector 
contained a dhfr cDNA sequence upstream of the heavy chain sequence but a 
cytomegalovirus splice donor was inserted upstream of dhfr and an SV40 splice acceptor 
site downstream of dhfr, so that the dhfr coding region would be expected to be spliced 
out of the mature heavy chain mRNA. To the extent that this splicing fails, dhfr would be 
expressed.  After transfection of this engineered vector and selection in –GHT medium, 
each step in MTX amplification resulted in the isolation of cells with a higher copy 
number than those isolated using transfection followed by amplification with a normal 
vector.  This occurs since resistance to a certain MTX level depends on functional dhfr 
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being expressed.  In this case the number of dhfr gene copies must be higher than the 
usual case in which all transcripts yield a functional dhfr mRNA since only a fraction of 
dhfr transcripts are properly spliced.  Thus, this scheme allows the use of lower MTX 
concentrations at each amplification step to isolate cells with increased copy number.  
This strategy allows for more rounds of amplification before reaching the maximum 
MTX concentration at which selection for high copy numbers is effective and thus leads 
to the ultimate isolation of cells with higher copy numbers and production levels.  This 
strategy is shown in Fig. 2.  
 
Figure 2.  Enhanced amplification of dhfr using leaky splicing.  
A dhfr cDNA gene is inserted into an intron in an IgG gene. In the rare instances in 
which it is not spliced out, it acts as an mRNA and is translated into DHFR enzyme.  The 
low initial levels of DHFR confer ability to grow in purine-free medium but at the same 
time a high sensitivity to MTX and thus more dynamic range for amplification.  
 
Production from clones containing this engineered vector were compared to a 
standard vector containing light and heavy chain genes for both anti-VEGF (vascular 
endothelial growth factor) antibody and HGAb (human glioma antibody).  Using this 
method, MTX amplification using a standard vector accounted for an 18.4 fold increase 
in anti-VEGF antibody and a 17.6 fold increase in HGAb antibody production, both 
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compared to cells that were not subject to amplification.  A 1.6 and 1.5 fold increase in 
antibody secretion was observed using the engineered vector compared to amplified cells 
using the standard vector for anti-VEGF antibody and HGAb antibody respectively 
(Xiong et al., 2005).  This effort describes engineering of a vector that reduces the effort 
required to isolate a high-producing clone through a more stringent amplification 
protocol.  Although the end result of this protocol is the isolation of a moderately higher 
producer, most of the secretion increase is still attributed to amplification and the 
development time is still time consuming.   
 
Destabilization sequences on dhfr markers 
 
Other techniques have been investigated to reduce selection marker strength in order to 
isolate higher producing clones.  A method was developed that utilizes both mRNA and 
protein destabilizing sequence elements (Ng et al., 2007) to decrease the yield of DHFR 
per gene copy.  If the dhfr marker is engineered to contain elements that act to destabilize 
its mRNA or the enzymatic activity of its product, it must integrate into the genome at a 
location favoring high expression for clones to survive (Gross and Hauser, 1995).  The 
result is then an increase in the expression of the gene of choice since the marker and 
gene for the drug integrate at the same location.  Naturally occurring sequences in the 3’ 
untranslated region (UTR) have been found that act to destabilize mRNA .  One such 
sequence is an AU-rich element (ARE), a nonamer containing exclusively adenine and 
uracil (Guhaniyogi and Brewer, 2001).  Another type of destabilizing element, known as 
the PEST region, is from murine ornithine decarboxylase (MODC) and signals rapid 
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degradation of the enzyme.  The very short half life of MODC is critical to its 
functionality (Rogers et al., 1986).  
  Vectors have been engineered containing both the dhfr marker gene and the gene 
for interferon-gamma (IFNγ), a biotherapeutic cytokine.  Vectors containing these 
destabilizing elements for DHFR were compared to standard vectors by analyzing IFNγ 
production using ELISA (enzyme-linked immunosorbent assay).  One engineered vector 
contained only the ARE element for dhfr mRNA destabilization, another contained only 
the MODC PEST region for DHFR enzyme degradation, and a third contained both 
destabilizing elements.  Production titers of recombinant IFNγ using the vector 
containing both destabilizing sequences were found to be the highest.  The addition of 
ARE, MODC PEST, and both sequences resulted in a 1.1, 3.7, and 12.6 fold 
improvement in IFNγ productivity respectively.  This result was also seen by performing 
quantitative polymerase chain reaction (qPCR) measurements on cDNA molecules 
isolated from the different transfectants.  Experiments also showed that this method can 
be used in conjunction with MTX amplification since these destabilizing elements do not 
affect the gene amplification process (Ng et al., 2007).  These results show that the 
destabilization of the dhfr marker mRNA and enzyme product successfully isolated 
higher producing clones since many more copies of the therapeutic transgene are required 
for their survival in selective medium.  This technique shows a significant increase in 





Vector enhancers to promote higher production levels of biopharmaceuticals 
 
Instead of specifically integrating the therapeutic protein gene into a favorable 
expression location, transcriptional enhancing elements can be included in the gene 
vector itself. One such element is the gene promoter, which can be modified to maximize 
the expression of the gene.  Another example of these elements is regulatory sequences 
that are responsible for remodeling chromatin, allowing the promoter of the gene to be 
accessible to transcription machinery.  Two of the latter elements that will be discussed 




One of the more obvious means to achieve high levels of gene expression is to 
insert a strong promoter upstream of the therapeutic gene.  Previously used strong 
mammalian  promoters include that for the cytomegalovirus (CMV), the beta-actin 
promoter (Page and Sydenham, 1991), and the EF-1α  promoter (Allison et al., 2003).  
More recently, methods developed for protein engineering allow modification of 
promoters to enhance expression strengths.  One such method used error-prone PCR to 
create a diverse library of promoters derived from a constitutive bacteriophage PL-λ 
promoter that could be cloned into a vector to drive the expression of GFP in E. coli 
(Alper et al., 2005).  The library exhibited a very wide range of fluorescence intensities.  
The utility of such a promoter library can allow one to isolate a promoter of the greatest 
strength by assaying for the gene.  GFP fluorescence, mRNA levels quantified using 
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quantitative RT-PCR, and a minimum inhibitory concentration (MIC) of chloramphenicol 
applied to cells containing a gene vector for chloramphenicol acetyltransferase all 
showed a strong correlation, indicating that promoter engineering is generally effective.   
The promoter engineering technique was successfully applied to maximize growth yield 
and lycopene production in E. coli through control of the genes ppc and dxs, which 
produce phosphoenolpyruvatecarboxylase and deoxy-xylulose-P synthase respectively 
(Alper et al., 2005).  Creation of a promoter library was extended to mutation of the 
TEF1 promoter to drive yellow fluorescent protein (YFP) synthesis is S. cerevisiae.  This 
extension showed that promoter engineering can be used to achieve a desired phenotype 
in both prokaryotic and eukaryotic cells.  
Utilization of this method as a means of increasing biopharmaceutical production 
and shortening development time has not been explored in CHO cells or other candidate 
mammalian cells.  Despite the initial time investment to develop a promoter for CHO 
cells expressing biopharmaceutical products, the use of an engineered promoter may 
prove to be a powerful method that could be combined with many of the other strategies 
described below.  
Other promoters that have been investigated for maximizing production of 
biopharmaceuticals include the G1 phase specific growth-arrest and DNA damage 
inducible GADD153 promoter and the inducible MMTV promoter.  The GADD153 
promoter is active under serum-free conditions and in the G1 phase of the cell cycle.  
Secreted alkaline phosphatase (SEAP) and enhanced green fluorescent protein variant 
d2EGFP productivity under control of this promoter was highest in CHO cells at the G1 
phase in medium without serum (de Boer et al., 2004).  It was also shown that production 
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of both proteins under control of more commonly used promoters CMV and simian virus 
SV40 promoter was highest in complete medium at the S1 phase (de Boer et al., 2004).  
Since most cells during production are cultured in serum-free medium and exist in the G1 
phase, the GADD153 promoter may be useful in increasing production of 
biopharmaceuticals in CHO cells.  In another study, SEAP production in CHO cells was 
increased by more than 4-fold when induction of the MMTV promoter occurred at a high 
cell density when compared to induction at a low density (Lipscomb et al., 2004).  By 
utilizing this inducible promoter at maximum cell density in a reactor, volumetric 
productivity can be maximized. 
 
Chromatin opening elements 
 
The specific genetic elements responsible for maintaining an open chromatin 
structure in the region of highly expressed genes are currently unknown.  UCOEs 
(ubiquitous chromatin opening elements) are methylation-free CpG islands that possess a 
chromatin opening function making a DNA region more accessible to transcription 
machinery (de Poorter et al., 2007).  CpG islands are regions with many unmethylated 
CpG dinucleotides.  Methylation of this region is known to inhibit expression of a gene. 
One study investigated the use of CpG islands to inhibit transcriptional silencing and 
concomitant unstable expression of a transfected gene (Antoniou et al., 2003). In this 
study a vector was designed containing either TBP-PSMB1 (human TATA binding 
protein proteasome component B1) (Imbert et al., 1994) or hnRNPA2B1-CBX3 
(heterogeneous nuclear ribonucleoprotein A2/B1) (Biamonti et al., 1994), ubiquitously 
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expressed housekeeping genes that naturally contain a methylation-free CpG island that 
extends over two divergently transcribed promoters (Kozu et al., 1995; Trachtulec et al., 
1997).  FACS analysis showed that a GFP reporter was stably expressed at high levels 
when transfected with the dual promoters from these housekeeping genes containing 
many CpG islands.  This stable high expression was also evident when the gene was 
transfected at a poor location for stable expression such as within centromeric 
heterochromatin.  These results suggest that expression vectors containing therapeutic 
genes based on dual promoter CpG island regions can provide high level, stable 
expression for maximum production of a therapeutic protein in mammalian cell lines and 
can ameliorate sensitivity to the location of vector integration in the genome.  This result 
was confirmed by showing the inclusion of an UCOE enhanced expression of a CMV-
driven cDNA cassette in stably transfected CHO cells (Benton et al., 2002).  It was also 
shown that inhibiting histone deacetylation with sodium butyrate caused up to a 16-fold 
increase in reporter gene expression (de Poorter et al., 2007).  Valproic acid can also be 
used as a cost effective alternative to sodium butyrate (Backliwal et al., 2008b). 
 
Chromatin Attachment Regions 
 
Another study was focused on scaffold or matrix attachment regions (S/MARS) 
of DNA and how they affect chromatin structure and consequently gene expression 
(Girod and Mermod, 2003). S/MARS are genomic DNA sequences at which chromatin is 
anchored to the nuclear matrix during interphase (Mirkovitch et al., 1984).  S/MARS are 
also known to be linked to histone hyperacetylation which indirectly recruits DNA 
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demethylase to demethylate DNA in order to make it accessible for transcription (Jost et 
al., 2001; Zhu et al., 2001).  Results of in situ hybridization studies revealed that actively 
transcribed genes tend to be associated with the nuclear matrix.  Previous studies revealed 
that S/MARS augment the expression of a reporter protein in stably transfected 
mammalian cell lines (Stief, 1989).  In standard scenarios where the aim is to achieve a 
high gene copy number for maximum production, production increases are not always 
proportional to copy number increases since the amplified genes are in locations with 
varying expression characteristics.  Experiments have shown that when each gene copy 
was flanked by an S/MAR, genes were expressed at levels proportional to copy number.  
Additional work has shown that genes proximal to S/MARS are expressed at higher 
levels than distal genes (Bode et al., 2000).   
Protein production in CHO cells was tested using S/MARS to assess whether or 
not production would be improved through stronger gene expression.  Chicken lysozyme 
(cLys) S/MARs (Bonifer et al., 1997) were added to two expression plasmids coding for 
heavy and light chain immunoglobulin (IgG).  S/MAR elements increased IgG 
production in CHO cells 5-10 fold when S/MAR sequences flanked the coding gene 
(Zahn-Zabal et al., 2001).   
Although technology using chromatin opening elements and chromatin 
attachment regions has proven to be useful in the CHO cell platform, the production 
increases are not as high as those associated with standard MTX amplification.  However, 
further optimization of this method may achieve acceptable levels of protein with fewer 
rounds of amplification, and thus may decrease development time. 
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Utilizing gene targeting techniques for improved biopharmaceutical production 
 
An approach fundamentally different from those described above is intended to 
increase recombinant protein production by specifically integrating a vector at a location 
with favorable expression characteristics.  This goal can be approached by using site-
specific recombination systems in the genome, a procedure that is in contrast to standard 





One gene targeting technique utilized a Cre/loxP recombination system for 
targeting genes to sites in the genome that exhibit high expression levels (Kito et al., 
2002).  Cre recombinase is an enzyme that catalyzes the integration of a DNA sequence 
within a 34 base pair recognition site known as a loxP site.  This reaction is reversible 
since after integration, two loxP sites are present and act as substrates for the enzyme to 
catalyze excision of the DNA sequence between these sites.  Despite this disadvantage, 
the Cre/loxP system has a recombination specificity of about 80% (Raymond and Soriano, 
2007).  A vector was constructed that contained the genes for green fluorescent protein 
(GFP) and dhfr downstream of a loxP recognition site.  After transfection into DHFR-
deficient CHO cells, clones with the highest fluorescence were selected.  Clones were 
then screened for a further increase in fluorescence after MTX amplification.  The 
resulting clones could be deemed both transcriptionally active and gene amplifiable.  In 
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the next step a targeting vector containing the antibody light and heavy chain genes fused 
to a hygromycin resistant marker and a loxP site was co-transfected along with Cre 
recombinase to catalyze the site-specific recombination.  The result was the integration of 
the gene into a locus that is transcriptionally active and gene amplifiable.  This resulted in 
clones producing 160 mg/L of human monoclonal antibody in 7 days in a spinner flask 
(Kito et al., 2002), a substantial improvement compared to the previously reported value 
of 40 mg/L obtained under similar conditions (Colcher et al., 1989).  This procedure 
shows a significant improvement in production and decreased development time since 
gene integration is occurring at a location that has been pre-selected for its ability to 
amplify.  This method may decrease the time-consuming amplification process by 
requiring less amplification in order to reach an acceptable production level. This method 
only requires an initial fluorescent screen to determine the optimum cell line. Once 
isolated, a gene coding for any therapeutic protein can be targeted to that location to 
exhibit the favorable expression and amplification characteristics.  This gene targeting 
procedure also requires the use of Cre recombinase to perform the Cre/loxP 




A similar study incorporated the use of an analogous gene targeting system 
known as the Flp/FRT recombination system.  In this system the enzyme Flp 
recombinase catalyzes the recombination of gene sequences that are tagged with a FRT 
sequence.  This reaction is also reversible, similar to the Cre/loxP system.  Unlike 
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Cre/loxP, the Flp/FRT system has a poor recombination efficiency (<10%) (Raymond 
and Soriano, 2007).    Researchers (Huang et al., 2007) screened different gene 
integration sites using a vector with two weakened markers (β-galactosidase and dhfr).  
This vector contained a FRT sequence for subsequent recombination into the 
transcriptionally active sites.  After selection of 20 candidate clones with amplifiable 
expression sites, three were successfully used as hosts for Flp recombination of antibody 
genes.  The highest producing cell line was capable of producing 200 mg/L of full-length 
anti-CD20 antibody after 6 days of culture in a spinner flask.  Clones were also isolated 
that were high producers of human anti-SARS antibody and scFv-Fc fusion protein, 
indicating that this technique can be applied to a broad range of antibodies (Huang et al., 
2007).  Zhou et. al. performed similar work using the Flp/FRT recombination system 
with a target vector tagged with FRT and a neomycin resistance marker.  They isolated 
high producing clones of tissue plasminogen activator (tPA).  The most productive cell 
line was capable of producing 17.1 µg/106cells/day (Zhou et al., 2007).  This method is 
very similar to the Cre/lox recombination method and has the same advantages and 
drawbacks. 
 
ΦC31 integrase recombination 
 
 Another recombination system known as the ΦC31 system has an advantage over 
the two aforementioned systems in that the recombination reaction is irreversible.  The 
ΦC31 integrase catalyzes recombination between an attP and attB site which are different 
sequences.  The resulting recombination creates two hybrid sites that are no longer 
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substrates for the integrase, thus making the process irreversible.  A second advantage is 
that several genomic pseudo-attP sites with high sequence similarity to the correct attP 
sequence can act as substrates for the enzyme, thus catalyzing integration into these sites.  
A disadvantage of ΦC31 when compared to Cre/LoxP is that ΦC31 integrase 
recombination specificity is less than 10%, similar to Flp recombinase.  This issue has 
been solved through protein engineering efforts that created a mouse codon-optimized 
mutant of ΦC31 integrase known as ΦC31o (Raymond and Soriano, 2007).  This mutant 
enzyme is shown to have a recombination specificity almost identical to Cre recombinase.   
Integration into mammalian pseudo-attP sites can be advantageous.  CHO cells were co-
transfected with a plasmid transcribing the ΦC31 enzyme and a plasmid containing an 
attB site for integration into pseudo-attP sites and the gene for luciferase.  Luciferase 
expression was found to be 60-fold higher using this recombination system compared to 




 An Artificial Chromosome Expression (ACE) system utilizes murine artificial 
chromosomes (MACs) engineered to contain >50 site specific recombination sites (attP) 
specific to lambda integrase.  These engineered chromosomes are generated de novo in a 
host cell line and then purified away from the natural chromosomes.  They are then 
introduced into a recipient cell line suitable for biopharmaceutical production 
(Lindenbaum et al., 2004).  After stable incorporation of the chromosome into this new 
host cell line, a target vector carrying an attB site and containing the gene of interest and 
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a vector coding for lambda integrase are co-transfected into the cells.  Upon successful 
recombination, a drug resistant marker gene such as hygromycin becomes joined to an 
SV40 promoter conferring drug resistance.  A second loading can be performed using a 
different drug marker such as zeomycin to further increase expression (Lindenbaum et al., 
2004).  This second loading required about an extra 2 months to generate clonal 
candidates; however it increased production titers by about 50% (Kennard et al., 2007).   
CHO cell lines have been used as a host for the ACE system to produce a human 
monoclonal IgG1 antibody.   Candidate CHO clones were isolated in under 6 months and 
achieved titers of over 1g/L under non-optimized conditions making the ACE system 
competitive (Kennard et al., 2009).  Use of such a technology may increase development 
costs and could save time as gene amplification was not used.   
 
Each of the methods mentioned above aimed at increasing therapeutic protein 
production while minimizing development time and costs.  They are tabulated in Table 1 
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Efficient isolation of high-producing CHO clones for biopharmaceutical products 
continues to be an industrial challenge.  Standard methods are very time consuming and 
need improvement.  While utilizing technology such as FACS or automated colony 
pickers based on fluorescence allows high-throughput selection, the procedures are often 
expensive and needful of constant modification to adapt to different cell lines and protein 
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products.  The recent work involving vector engineering and site-specific recombination 
has shown promising results in isolating very high-producing clones.  Implementation of 
such strategies has the potential to increase overall production titers of biopharmaceutical 
drugs and reduce the time required to isolate useful amounts of protein for pre-clinical 
evaluation.   
A dual marker amplification strategy increases the maximum production of high-
producing clones but increases development time.  Utilizing vectors that weaken the dhfr 
selection marker still require time-consuming MTX amplification for maximum product 
yield.  Site-specific recombination techniques that identify locations in the genome with 
favorable expression characteristics can decrease the time required to isolate high-
producing clones.  Although these strategies require both initial screening for amplifiable 
sites, this process only needs to be performed once to produce a cell that can be utilized 
to produce a range of desired gene products. However, the use of a site-specific 
recombinase may increase development costs.  Use of an optimized promoter within the 
vector containing the gene for the biopharmaceutical of choice has potential to decrease 
development time but has not been sufficiently tested in CHO cells or other mammalian 
production platforms.  Utilization of other vector enhancers that make genes coding for 
the drug of choice accessible to transcription machinery has been explored in CHO cells 
and does not result in production increases comparable to MTX amplification.  
Nevertheless, high producers can be isolated in a short period of time which obviates the 
need for a lengthy amplification step, and these techniques could be combined with an 
abbreviated amplification regimen. Overall, progress toward decreasing development 
time of high-producing clones has been made.  The methods reviewed also show progress 
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toward increasing maximum therapeutic protein productivity per cell.  These 
enhancements appear largely independent of the therapeutic protein being produced and 
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Co-amplification of transgenes using the dihydrofolate reductase/methotrexate 
(DHFR/MTX) system is a widely used method for the isolation of Chinese hamster ovary 
(CHO) cell lines that secrete high levels of therapeutic and diagnostic proteins. A 
bottleneck in this process is the stepwise selection for MTX-resistant populations; which 
can be slow, tedious and erratic. We sought to speed up and regularize this process by 
isolating dhfr– CHO cell lines capable of integrating a transgene of interest into a defined 
chromosomal location that supports a high rate of gene amplification. We isolated 100 
independent transfectants carrying a minigene for human adenosine deaminase (ada) 
linked to a φC31 attP site and a portion of the dihydrofolate reductase (dhfr) gene. 
Measurement of the ada amplification rate in each transfectant using Luria-Delbruck 
fluctuation analysis revealed a wide clonal variation; sub-cloning showed these rates to 
be heritable. Site directed recombination was used to insert a transgene carrying a 
reporter minigene for secreted embryonic alkaline phosphatase (SEAP) into the attP site 
at this location in a high amplification rate clone (DG44-HA4). Subsequent selection for 
gene amplification of the reconstructed dhfr gene yielded reproducible rates of seap gene 
amplification and concomitant increased levels of SEAP secretion. This cell line as well 
as this method of screening for high amplification rates may prove helpful for the reliable 
amplification of recombinant genes for therapeutically or diagnostically useful proteins.  
 









CHO, Chinese hamster ovary; DHFR, dihydrofolate reductase; MTX, methotrexate; 
ADA, adenosine deaminase; dCF, deoxycoformycin; SEAP, secreted embryonic alkaline 
phosphatase; PTF, purine and thymidine free.  
 
1.  Introduction 
 
The phenomenon of gene amplification is often exploited to produce therapeutic 
recombinant proteins, monoclonal antibodies being the prime example. A gene or genes 
coding for the therapeutic protein(s) of choice (i.e. monoclonal antibody heavy and light 
chain) are transfected into a host cell along with a selectable drug-resistance marker gene. 
After an initial isolation of transfectants exhibiting a minimal level of drug resistance, 
selection for transfectants that have acquired a modestly higher level of resistance by 
virtue of amplification of the marker gene is carried out. Many iterations of this selection 
process can result in cell clones with a high level of resistance, a high level of marker 
gene expression, and a high number of copies of the marker gene. Since the size of the 
amplified region is much larger than a single gene (Hamlin, 1992) and since transfected 
genes usually co-integrate in the host genome, even when co-transfected on separate 
plasmids (Chen and Chasin, 1998), the gene of interest is also co-amplified and its 
protein produced at a high level (Wigler et al., 1980).    
 
A popular system for this approach uses a minigene specifying the enzyme dihydrofolate 
reductase (DHFR) as the selective marker (Ringold et al., 1981), methotrexate (MTX) as 
the drug and a Chinese hamster ovary (CHO) cell line deficient in this ubiquitous enzyme 
(Urlaub and Chasin, 1980; Urlaub et al., 1983) as a host. CHO cells are capable of gene 
amplification, a trait not shared by normal cells (Livingstone et al., 1992; Wahl et al., 
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1984a; Yin et al., 1992). In this case the target of the drug is DHFR, and resistance is 
gained by overproducing it. Transfected cells are cultured in a medium lacking a source 
of purine and thymidine nucleotides.  Since DHFR-deficient host cells are unable to 
synthesize these metabolites only the transfectants can grow. MTX is a specific and tight-
binding inhibitor of DHFR, but cells that have undergone dhfr amplification 
(“amplificants”) can overcome a judiciously chosen concentration of the drug.   
 
Although the dhfr-MTX gene amplification method can result in as much as a 500-fold 
increase in gene copy number (Hamlin, 1992), it suffers from long and variable 
development times. Each amplification step brings about only a modest increase in gene 
copy number, thus severely limiting the concentration of MTX that can be applied at each 
step. It is common to take six months or longer to isolate a cell line with the desired 
recombinant protein production level. This time bottleneck inhibits the rapid testing of 
multiple new candidates for pre-clinical evaluation and ultimately limits how quickly a 
new drug candidate gets to market (Trill et al., 1995).  
 
Although the factors influencing gene amplification are not well understood, it has been 
shown that clones within a CHO transfectant population exhibit a wide distribution in the 
yield of amplificants (Kito et al., 2002; Wahl et al., 1984b). The simplest explanation for 
this variability is a position effect within the CHO genome. We reasoned that the gene 
amplification regimen could be both shortened and made more reliable by inserting the 
gene of interest along with the dhfr minigene at a defined locus in the CHO genome 
chosen for supporting a high amplification rate. We identified such sites by screening 100 
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transfectants for their rate of amplification (as opposed to the frequency of amplified 
cells) using Luria-Delbruck fluctuation analysis. A chosen site could subsequently be 
used to insert genes of interest via an included site-specific recombination sequence. A 
winning clone was shown to amplify a dhfr minigene along with a gene of interest at a 
rate higher than randomly integrated transfectants and to secrete the protein of interest at 
increased levels. This clone or similarly isolated clones may prove advantageous for 
those using gene amplification in CHO cells to drive high level production of 
therapeutically or diagnostically useful proteins.  
 
2.  Materials and methods 
 
2.1 Plasmid construction 
 
We constructed a vector (pKAPD1) to be transfected into host DHFR-deficient CHO-
DG44 cells (Urlaub et al., 1983) with a neomycin resistance gene and an amplifiable 
human adenosine deaminase (ada) gene. A portion of the dhfr gene and a φC31 attP site 
were included for subsequent recombination and amplification steps. A fragment 
containing the dhfr promoter, exon 1 and part of intron 1 was isolated by PCR using 
primers appended with AscI restriction site ends (forward: 
ACGTAGGCGCGCCGGGGCCTCTGATGTTCAAT; reverse: 
ACGTAGGCGCGCCCCCCTCATGACTGTCCCTAA), digested with AscI, and ligated 
into an AscI site sequence that had been inserted into a unique BglII site on plasmid 
pEGFP-C3 so as to retain one BglII site (ClonTech). A synthetic 39 bp attP site for φC31 
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recombinase (Thyagarajan et al., 2001) was then ligated into the unique BglII site on this 
plasmid (pKPD1) downstream of the dhfr insert. A human adenosine deaminase gene 
(ada) driven by a CMV promoter was isolated by ApaLI digestion from plasmid 
pCMVada (American Type Culture Collection). The insert was ligated into the unique 
ApaLI site in pKPD1 to create vector pKAPD1 containing the dhfr promoter and exon 1, 
the attP site, a kanamycin/neomycin resistance gene, and the ada gene in that order (Fig. 
1). Next, we constructed a plasmid (pBE26) to be used for recombination into the 
aforementioned attP site containing an attB site, the remaining 3’ portion of the dhfr gene, 
and a seap gene coding for secreted embryonic alkaline phosphatase (SEAP) for future 
protein assays.  A plasmid was first created by removal of the dhfr promoter, exon 1 and 
part of intron 1 from pDCH1P11 by digestion at a unique SmaI site upstream of the 
promoter and a unique PstI site within intron 1. The plasmid pDCH1P11 was previously 
constructed (Noe et al., 1999) by cloning a dhfr minigene, driven by the dhfr promoter 
and containing only intron 1 and one natural polyadenylation signal, between unique 
SmaI and HindIII restriction sites in pSP72 (Promega). A synthetic 34 bp φC31 
recombinase attB site (Thyagarajan et al., 2001) was ligated between these restriction 
sites so as to lie within intron 1, upstream of the contiguous dhfr exons 2 through 6. To 
create a vector (pSEAPBE26, Fig. 3) directing the synthesis of SEAP, a region of pBE26 
comprised of the attB site, dhfr exons 2 through 6 and a dhfr polyadenylation site was 
isolated by PCR using primers with NotI restriction site ends (forward: 
ACGTAGCGGCCGCGCCGATTCATTAATGCAGGT ; reverse: 
ACGTAGCGGCCGCTGCTCTCAGGGGCTCTATGT) and ligated into the unique NotI 
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site in the plasmid pCMVSEAP (Addgene #24595) downstream of the seap gene driven 
by a CMV promoter.  
 
2.2 Stable transfection 
 
Vector pKAPD1 was linearized by digestion at a unique AgeI restriction site and 
transfected into host CHO DG44 cells by electroporation with low input DNA levels to 
promote single copy integration.  Stable transfectants were selected with 800 µg/ml G418 
for 2 to 3 weeks with medium renewals about every five days. One hundred colonies 
were isolated with cloning cylinders, expanded and frozen.   
 
2.3 Fluctuation tests 
 
Fluctuation analysis was used to measure the rate of amplification of the adenosine 
deaminase (ada) gene (Kaufman et al., 1986). High levels of this enzyme afford 
resistance to a combination of high adenosine and deoxycoformycin (dCF), an ADA 
inhibitor, as described in Results. A pilot study performed with several transfectant 
clones showed that the inclusion of 0.5 µM deoxycoformycin reduced survival in the 
presence of 1.1 mM adenosine to an average of about 10 colonies per 106 treated cells 
and that dCF resistance in DG44 transfectants arises by amplification of the transgene, as 
described previously (Kaufman et al., 1986).  Each of the 100 stable clones was seeded 
into 12 wells of a 96-well dish at a density of approximately 10 cells per well so that 
inclusion of a preexisting amplificant was highly unlikely. Cells in each well were grown 
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to confluence and then expanded into 12 wells in 6-well dishes. At about 75% confluence 
the cells in each well were challenged with 0.5 µM dCF plus 1.1 mM adenosine for 2 to 3 
weeks. Surviving colonies were fixed with 3.7% formaldehyde and stained with crystal 
violet. Colony counts from the 12 wells were used to calculate an amplification rate 
(events/cell/generation) using the P0 and mean methods (Luria and Delbruck, 1943) and 
the median method (Lea and Coulson, 1949).  A given method did not always allow a 
calculation of an amplification rate; in these cases we were still able to calculate a 
maximum or minimum rate, as follows. Sometimes all 12 cultures yielded dCF-resistant 
colonies, undermining the calculation of P0, the proportion of cultures yielding no 
colonies. In these cases we estimated a minimum amplification rate by assuming that the 
thirteenth culture would have yielded no colonies, i.e., a P0 of 1/13. In the opposite 
situation, when none of the 12 cultures yielded resistant colonies we assumed the 13th 
culture would have yielded colonies, for a P0 of 12/13, so that the amplification rate was a 
maximum estimate.  In other cases some wells contained colonies too numerous to count; 
here we assigned a value of 40 to the number of colonies; and so the estimate of the 
amplification rate using the mean or median methods was a minimum. Candidate clones 
were subcloned using limiting dilution and the measurements of amplification rates were 
repeated.  
 
2.4 Dhfr and seap co-amplification and expression 
 
To target the site specific recombination site, cells were co-transfected with pSEAPBE26 
and pPGKPhiC31obpA (Addgene #13795, ref. (Raymond and Soriano, 2007)) for 6 
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hours using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions 
and selected for a functional dhfr gene by growth in purine and thymidine free medium 
(“PTF” medium: Alpha MEM without nucleosides and deoxynucleosides, Thermo 
Fisher) for 2 to 3 weeks. To generate transfectants that had undergone random 
integrations, cells were co-transfected with the vector pCMVSEAP for SEAP production 
and pDCH1P11 containing a complete dhfr minigene for amplification. MTX 
amplification was performed on the pools of stable transfectants that survived in each 
case. The concentrations of MTX used can be seen in Fig. 4; 2 to 3 weeks were allowed 
to gauge survival at each step. After isolation of DNA from these pools, copy numbers of 
seap were determined by triplicate real time PCR measurements using Sybr Green 
staining in an Applied Biosystems 7000 instrument. To determine absolute seap copy 
numbers, we set the value found for female human genomic DNA (Promega) equal to 
four, as the primers used (forward: GGCACTGACTGAGACGATCA; reverse: 
GAGAAGACGTGGGAGTGGTC) are able to amplify both the placental and the 
placental-like seap genes. The amount of secreted SEAP from each pool of cells was 
measured after a 24 hour accumulation period in serum-free medium using the SensoLyte 
pNPP Secreted Alkaline Phosphatase Reporter Gene Assay Kit (Colorimetric), from 
AnaSpec (Cat # 72144) with p-nitrophenyl phosphate as a substrate. Absorbance readings 
were taken at 405 nm after 30 minutes and related to a standard curve using purified 
SEAP provided in the Sensolyte kit assayed in the presence of serum free medium. 








Our goal was to isolate a DG44 cell with a site-specific recombination site at a location 
where gene amplification occurs at a relatively high and reproducible rate. Our plan was 
to transfect DG44 cells with a plasmid carrying a site-specific recombination site linked 
to a minigene that can act as a selective marker for gene amplification. One hundred 
independent transfectant clones, each presumed to carry this construct at a different 
location, would be isolated. The gene amplification rate of each transfectant clone would 
be measured and a winner chosen for further study.  
 
We used a plasmid  carrying  the attP from φC31 (Thyagarajan et al., 2001) for site 
specific recombination and a human adenosine deaminase (ada) minigene for measuring 
gene amplification.  High concentrations of adenosine inhibit the growth of most 
mammalian cells, but this inhibition can be reversed by high cellular levels of ADA, 
which detoxifies adenosine by catalyzing its deamination to inosine. Deoxycoformycin 
(dCF) is a potent ADA inhibitor that counteracts this detoxification. Cells in which the 
ada gene has been amplified can overcome the inhibition caused by a marginal amount of 
dCF (Ingolia et al., 1985). In particular, the use of an iterated selection for resistance to 
dCF in the presence of high adenosine has been successfully used for amplification of an 
ada minigene in CHO dhfr– cells (Kaufman et al., 1986).  
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It is important to note that amplification rates cannot be determined by simply comparing 
the frequency of dCF-resistant colonies arising from each transfectant clone, as this 
frequency is dependent not only on the rate at which amplificants are generated, but also 
on their subsequent growth in each culture. For instance, an amplification event that 
occurred at an early time in the growth of a culture will yield a high number of colonies 
even if such events occur at a modest rate. Fluctuation analysis was developed by Luria 
and Delbruck to separate the event rate from the products of those events (Luria and 
Delbruck, 1943). As applied here, the frequency of appearance of dCF-resistant colonies 
in a series of 12 parallel cultures is measured; assuming a Poisson distribution of 
amplification events, the rate of amplification can be calculated from the proportion of 
cultures with no resistant colonies (Po method), or from the variance or the median of the 
number of such colonies per culture. This type of analysis has been applied to both 
mutation rates (Chasin, 1973) and gene amplification rates (Tlsty et al., 1989) in 
mammalian cells. One hundred transfectant clones would then be individually screened 
for the rate of ada gene amplification on the basis of their resistance to a combination of 
high adenosine and dCF. 
More specifically, we transfected DG44 cells with a plasmid carrying the attP site 
(Thyagarajan et al., 2001), an ada minigene, the 5’ part of a dhfr minigene, and a 
neomycin resistance marker (Fig. 1). One hundred colonies resistant to G418 were cloned 
and their ada amplification rates were measured as described above.   
 
 
Figure 1. DNA for measuring ada amplification rates.  The linearized DNA construct 
transfected into DG44 cells for integration into random locations in the genome.  
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3.2 Ada amplification rates 
 
Amplification rates (events per cell per generation) were measured for each of the 100 
transfected ada genes, each presumably integrated at a different random location.  Three 
methods were used: P0, mean, and median (see Methods). Amplification rates for 
individual transfectants ranged widely, from 0 (no amplification evident) to about 5x10-6 
amplification events per cell per generation. An exact rate could not always be calculated 
(e.g., no cultures with colonies or colonies too numerous to count); in these cases, a 
maximum or minimum rate, respectively, could be estimated. A complete list of the data 
is presented in Supplementary Data Table S1. The results for all 100 clones are shown in 
ranked order in Fig. 2A and as a distribution in Fig. 2B. Almost all of the clones with 
rates above 7 per million cells per generation included at least one estimated rate and so 
were considered less reliable. Three transfectant clones showing high amplification (HA) 
rates numbered 4, 35, and 63  (see arrows in Fig. 2A) were chosen for further study 
(DG44-HA4, DG44-HA35, and DG44-HA63). Clones DG44-HA4 and DG44-HA35 
yielded the highest amplification rates that were measurable by all three methods. Clone 
DG44-HA63 had an even higher amplification rate but its rate could only be measured 
with two of the methods (Supplemental Table S1). Subclones were isolated from each of 
these three clones to assess the heritability of the amplification rates. The subclones 





Figure 2.  Amplification rates of transfectant clones. A. Clones are shown ranked; 
points represent the average of the Po, mean and median methods. Open symbols show 
results for subclones of the clone in the same column. These clones (4, 35 and 63, left to 
right) were chosen for further testing.  B. Distribution of amplification rates; each bin 
number represents rates at or below that value and higher than the preceding value. Rates 






3.3 Gene amplification in high ada amplification rate clones 
  
We next sought to determine whether a transfectant clone exhibiting a high rate of 
amplification for ada would be capable of amplifying additional transgenes at a 
comparable rate if inserted into the φC31 attP site upstream of the ada minigene. For this 
experiment we used a plasmid carrying two informative sequences in addition to a φC31 
attB site for site-specific recombination. The first sequence was the downstream portion 
of the dhfr minigene comprised of part of intron 1 plus the fused exons 2 through 6; 
recombination between the attP and attB sites reconstitutes an active dhfr minigene after 
the two portions are joined within intron 1 (Fig. 3). This reconstituted dhfr gene was used 
to select for gene amplification by resistance to the DHFR inhibitor methotrexate 
(Nunberg et al., 1978). The second sequence was a cDNA-based minigene specifying 
human secreted embryonic alkaline phosphatase (SEAP). This enzyme is easily 
quantified and was used to gauge the usefulness of the transfectant clones for the 
production of secreted proteins of interest (Zhou et al., 2010). We chose clone DG44-








Figure 3.  Site specific recombination scheme. Exons 2 through 6 of dhfr and a full 
seap gene were integrated at the location of the attP site in transfectant clone DG44-HA4 
via site specific recombination with an attB site on the incoming plasmid pSEAPBE26. 
φC31 recombinase was provided by co-transfection. The result was a reconstituted 
functional dhfr minigene together with a functional seap gene integrated into the same 
locus that supported a high amplification rate for ada. Successful site specific 
recombination was selected for by growth in purine-free and thymidine-free medium 
afforded by the reconstituted dhfr gene. Jagged lines: chromosomal DNA; lower line 
joining dhfr exons: pre-mRNA splicing pattern.  
 
Clone DG44-HA4 was co-transfected with pSEAPBE26 and pPGKPhiC31obpA 
(recombinase) in three separate experiments, selecting for DHFR-positive populations by 
growth in purine and thymidine free (PTF) medium. Pooled survivors from each of these 
three experiments (4RA, 4RB and 4RC) were then tested for amplification of the 
reconstituted dhfr gene by selecting for step-wise resistance to MTX (0, 0.01, 0.02, 0.1, 
0.5, 5, and 20 µM). Resistance to 20, 20 and 5 µM MTX was ultimately achieved for 
4RA, 4RB and 4RC cells, respectively. In the case of 4RA, quantitative real time PCR 
(QPCR) was used to measure seap copy numbers at each stage of the selection. To 
determine the absolute number of seap genes at these stages we normalized the QPCR 
measurements to the value found with diploid human DNA (set to 4 due to the presence 
of two seap isozyme genes). As seen in Fig. 4, an overall amplification to about 600 
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copies of the seap gene was reached after 172 days. The original 4RA transfectants 
carried an average of 3 copies of the seap gene, but only one should be linked to the 
single functional reconstructed dhfr minigene so the fold amplification was 600. To 
verify that a dhfr minigene had been recombined into the φC31 attP site in clone 4RA, we 
PCR amplified the region spanning the predicted attL recombination joint. As expected, 
the recombined region appeared after transfection and this region was amplified after 
MTX selection (Fig. 5).   
 
 
Figure 4.  Gene amplification of transgenes in recombinant clones. Seap gene copy 
number was measured by QPCR after selection for dhfr gene amplification by 
methotrexate resistance as indicated. Closed circles: clone 4RA (site specific 
recombinant); open circles: clone 35A (random integration); open triangles: clone 63A 





Figure 5.  Recombined dhfr becomes amplified in clone 4. The region spanning the site 
specific recombination site (attL) was PCR amplified using primers depicted at the top. 
This joint appeared after transfection (compare 4RA vs. 4) and became amplified after 
MTX selection (compare 4RA20 vs. 4RA). Gapdh, a region of the glyceraldehyde-3-
phosphate dehydrogenase gene as a control; 4RA, clone DG44-HA4 transfectant selected 
for DHFR activity; 4RA20, clone 4RA selected for resistance to 20 µM MTX; M, 
HyperladderTM II (Bioline) molecular size markers.  
 
  
For comparison, we transfected a plasmid carrying a complete dhfr mini-gene (as well as 
a seap gene) so as to confer a DHFR-positive phenotype without site specific 
recombination. This plasmid was transfected into two other clones that exhibited high 
ada amplification rates: clones DG44-HA35 and DG44-HA63 (Fig. 2). Two independent 
transfections were carried out for each clone; no φC31 recombinase gene was co-
transfected in these experiments. Selection in PTF medium yielded transfectants (35A, 
35B, 63A, and 63B) that had integrated the complete dhfr gene at random sites (i.e., not 
requiring reconstitution). These cells were then subjected to MTX selection for dhfr gene 
amplification as above. For 35A and 63A resistance to 5 µM MTX was achieved, but 
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35B and 63B only reached resistance to 0.5 µM MTX. That is to say, no resistant 
colonies appeared at the next level of MTX challenge. Seap copy number measurements 
in the case of 35A showed gene amplification, but at a slower rate and to a lesser extent 
than the recombined 4RA cells. Surprisingly, 63A cells exhibited no evidence of gene 
amplification despite their resistance to high levels of MTX.  We attempted to perform 
the recombination reaction via co-transfection similar to clone 4, however we observed 
no colony formation upon selection in PTF medium.   This may be due to the inefficiency 
of the recombination reaction at the attP site in these clones.  Also, recombination 
reactions were not performed in higher amplification rate clones (above 4) since rate data 
for such clones was not obtained yet. 
 
The higher rate of amplification in the case of the plasmid recombined into the attP site 
(4RA) compared to random insertions (35A) is consistent with the idea that the higher 
rate of amplification is due to the chromosomal location of the former.  
 
3.4 Recombinant protein secretion in transfectant clones 
 
Along with gene copy number, we measured the secretion of SEAP in the cell cultures 
selected at each stage of the dhfr amplification process. SEAP enzymatic activity in the 
medium was assayed after a 24 hour accumulation at each selection step in all seven 
transfection/amplification experiments. As can be seen in Fig. 6A, SEAP secretion 
increased at a similar rate in the three experiments using the site specific recombinant 
DG44-HA4 (R2=0.89 using all points from the three experiments). Two independent full 
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dhfr minigene transfectants of clone DG44-HA35 exhibited increased SEAP secretion at 
a rate similar to that of DG44-HA4, although there was somewhat more variation 
(R2=0.67).  The same experiment with clone DG44-HA63 yielded a low rate of increase 
in SEAP secretion during the MTX selection, in agreement with the gene copy number 
results showing a lack of gene amplification in this transfectant (Fig. 4).  
 
 
Figure 6.  SEAP secretion during gene amplification. A. Transfection of a partial dhfr 
minigene into the φC31 attP site of DG44-HA4 to reconstitute a functional gene. The 
results of three independent amplification regimens with 3 independent transfectant pools 
are shown. Day zero is the day of transfection. Clone 4RC cells did not survive a 
challenge in 20 µM MTX.  B. Transfection of the full dhfr minigene into random sites in 
DG44-HA35 and DG44-HA63. The results of four independent amplification regimens 
with 2 independent transfectant pools are shown. Neither of these clones survived in 20 
µM MTX, and 63B cells did not survive a challenge in 5 µM MTX. 
 
4.  Discussion 
 
Our intention was to isolate a clone with a site specific recombination site located at a 
chromosomal position that yields a high rate of gene amplification. Such a clone could 
prove advantageous for the production of recombinant proteins by inserting the 
corresponding gene into that location. Previous studies (Gajduskova et al., 2007; Kito et 
al., 2002; Wahl et al., 1984b) showed that only a minority of cell transfectants (27 of 82, 
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2 of 16, and 1 of 4 respectively) are capable of efficient transgene amplification. 
Although high frequencies of gene amplification were documented in these and similar 
studies, there was no attempt to measure the amplification rate. Thus the high frequencies 
seen with individual transfectants could be due to the stochastic nature of the 
amplification process, such that an early event in any one experiment could be mistakenly 
interpreted to represent a high amplification rate. Here we have used fluctuation analysis 
to estimate amplification rates of 100 independent CHO cell transfectants. We saw a wide 
range of amplification rates among the transfectants: most transfectants exhibited low 
rates; two-thirds had rates that were less than the mean of 2 x 10-6. A test of 3 clones 
chosen from the top quartile showed that their amplification rate was heritable, ruling out 
a simple statistical origin and as predicted if the rate depends on chromosomal location. 
 
To see whether additional genes inserted in a recombination site would also be amplified 
at a high rate we transfected clone DG44-HA4 with a plasmid targeted to the 
recombination site. Successful recombination was selected for by the reconstruction of a 
functional dhfr gene and confirmed by PCR analysis. This plasmid also carried a 
transcription unit for SEAP. Three independently transfected populations derived from 
clone DG44-HA4 were subjected to a regimen selecting for increasing resistance to MTX. 
All three independently generated transfectant populations of clone DG44-HA4 
responded to MTX selection by secreting increased levels of SEAP. The rate of increase 
was remarkably reproducible, yielding an r2 value of 0.89 for the three transfection 
experiments combined (Fig. 6A). Stepwise amplification of the seap gene was confirmed 
by QPCR in one of the transfections, which ultimately generated approximately 600 
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copies of the seap gene. The seap gene here is standing in for a gene of interest; the 
reproducible increase in the production of the enzyme is consistent with the expectation 
that a targeted chromosomal location can confer reliability for recombinant protein 
production. In contrast, a pool of transfectants made up of random integrants of the full 
dhfr gene showed a lower amplification rate and more variability.  
 
Clone DG44-HA63 acquired drug resistance by a means other than dhfr gene 
amplification. Alternative mechanisms of MTX resistance include altered folate 
permeation (Flintoff et al., 1976) or amplification of the endogenous P-glycoprotein gene  
leading to increased drug efflux (Assaraf et al., 1989). Perhaps in the initial screen the 
dCF-resistant colonies arose by one of these mechanisms rather than by ada gene 
amplification. For example clone DG44-HA63 may have started out with one allele of a 
dCF permease gene knocked out or an earlier amplification of the P-glycoprotein gene.  
 
DG44 and DXB11, CHO  dhfr–  cell lines have been widely used for gene amplification 
in the service of recombinant protein production (Jayapal et al., 2007). As described, 
clone DG44-HA4 could represent an improvement over these cell lines for providing 
more reliable amplification. That is not to say that clone DG44-HA4 is the optimum 
clone for this purpose, even among the 100 integrants screened here. Clone DG44-HA4 
was chosen conservatively as exhibiting the highest average amplification rate of the 
three methods used among those with no estimated values and with a standard error of 
less than 10% of the average. It could be that one of the clones with a higher estimated 
amplification rate (e.g. ~8 x 10-6 cell-1 gen-1) would be a better choice.   
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A more general reason that clone DG44-HA4 may not always be the best general choice 
for gene amplification is that DG44 derivatives have been improved through genetic 
manipulation. As one example, considerable effort was invested in the isolation of a 
DG44 mutant lacking fucosyl transferase activity since unfucosylated immunoglobulins 
perform better in antibody dependent cellular cytotoxicity (Yamane-Ohnuki et al., 2004). 
In this and analogous cases, the method used here could be used to screen for an attP 
integration site supporting a high amplification rate in a special cell line.  
 
In the experiments reported here no effort was made to screen for a high expression. 
Rather, the focus was solely on amplification rate. The reasoning behind this strategy was 
that gene expression can be increased by genetic manipulation of the incoming vector, 
through for example the addition of powerful promoter/enhancers (Allison et al., 2003), 
ubiquitous chromatin opening elements (de Poorter et al., 2007) and/or insulator elements 
(Zahn-Zabal et al., 2001). The incoming dhfr gene could also be weakened by including 
mutations that decrease the efficiency of the splice site preceding exon 2 (Chen and 
Chasin, 1993) to provide a greater range of amplification by starting at a lower MTX 
concentration. 
 
In conclusion, we have described a method that can be used to select for mammalian cell 
clones with high and reliable rates of transgene amplification. The resulting clones could 
be used to facilitate the isolation of mammalian cell lines that produce recombinant 
proteins at high levels. 
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Amplification rate  
(events per cell per generation) 
Clone # P0 Mean Median Total Average 
1 1.10 1.28 1.70 1.36 
2 0.69 0.42 0.52 0.54 
3 0.69 2.11 0.52 1.11 
4 2.48 3.11 3.61 3.07 
5 0.08b 0.08 0.06 0.07 
6 0.18 0.24 0.06 0.16 
7 1.10 3.38 6.56 3.68 
8 0.69 1.75 0.52 0.99 
9 0.88 3.34 4.06 2.76 
10 0.29 0.28 0.06 0.21 
11 0.41 0.28 0.06 0.25 
12 0.41 0.28 0.06 0.25 
13 0.29 0.57 0.06 0.30 
14 0.08b 0.08 0.06 0.07 
15 0.41 0.28 0.06 0.25 
16 0.09 1.19 0.06 0.44 
17 0.08b 0.08 0.06 0.07 
18 0.29 0.28 0.06 0.21 
19 1.79 1.33 1.96 1.69 
20 0.41 0.28 0.06 0.25 
21 0.18 0.20 0.06 0.15 
22 0.69 0.73 0.52 0.65 
23 0.29 0.38 0.06 0.24 
24 0.41 0.28 0.06 0.25 
25 0.41 0.28 0.06 0.25 
26 1.10 1.35 1.70 1.38 
27 1.79 1.87 3.16 2.28 
28 1.10 1.10 0.85 1.02 
29 0.41 0.28 0.06 0.25 
30 0.69 2.23 1.96 1.63 
31 0.41 0.28 0.06 0.25 
32 0.88 0.57 0.85 0.77 
33 0.88 0.65 0.85 0.79 
34 0.88 1.56 1.15 1.20 
35 1.39 3.62 2.45 2.49 
36 1.39 2.25 3.16 2.27 
37 2.56a 1.89 2.21 2.22 
38 0.08b 0.08 0.06 0.07 
39 1.79 1.46 2.69 1.98 
40 1.39 2.09 2.69 2.06 
41 2.56a 3.55 6.56 4.23 
42 2.56a 6.71 14.56 7.94 
43 2.56a 3.09 5.54 3.73 
44 1.79 2.01 3.39 2.40 
45 2.56a 1.46 2.69 2.24 
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46 0.08b 0.08 0.06 0.07 
47 0.29 0.96 0.06 0.43 
48 2.56a 2.59 4.92 3.36 
49 2.56a 8.10c 16.31d 8.99 
50 2.56a 1.26 1.96 1.93 
51 2.56a 1.05 1.43 1.68 
52 2.48 1.33 1.96 1.92 
53 2.56a 7.64c 16.31d 8.84 
54 0.08b 0.08 0.06 0.05 
55 0.69 4.91c 9.10d 4.90 
56 0.88 1.43 1.15 1.15 
57 0.08b 0.08 0.06 0.05 
58 0.41 0.83 0.06 0.43 
59 0.18 1.46c 0.06 0.57 
60 0.69 1.37 1.43 1.16 
61 1.39 5.00c 9.85d 5.41 
62 0.08b 0.08 0.06 0.05 
63 2.48 6.61c 14.56d 7.89 
64 1.39 4.59c 4.71 3.56 
65 0.09 0.31 0.06 0.15 
66 1.39 5.57c 14.03d 7.00 
67 0.41 1.69c 0.06 0.72 
68 2.56a 8.62c 16.31d 9.17 
69 0.29 0.48 0.06 0.27 
70 0.88 2.57c 0.85 1.43 
71 2.56a 4.78c 7.36 4.90 
72 1.39 2.96c 4.49 2.95 
73 1.39 5.07c 8.14 4.86 
74 2.48 6.61c 16.31d 8.47 
75 2.56a 8.62c 16.31d 9.17 
76 0.69 3.48c 2.21 2.13 
77 0.09 0.62 0.06 0.26 
78 0.18 1.17 0.06 0.47 
79 0.08b 0.08 0.06 0.05 
80 0.54 0.51 0.06 0.37 
81 0.41 0.48 0.06 0.31 
82 0.29 0.59 0.06 0.31 
83 0.69 0.68 0.52 0.63 
84 0.54 1.24 0.06 0.61 
85 1.79 6.41c 16.31d 8.17 
86 0.41 0.78 0.06 0.41 
87 0.88 1.58 1.96 1.47 
88 2.56a 6.89c 16.31d 8.59 
89 1.39 1.89c 1.70 1.66 
90 0.69 4.31c 1.43 2.14 
91 1.39 1.37 1.70 1.49 
92 0.69 2.59c 0.85 1.38 
93 0.88 2.67c 1.43 1.66 
94 2.56a 4.38c 4.71 3.88 
95 2.56a 2.84c 2.69 2.70 
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96 0.29 0.54 0.06 0.29 
97 0.08b 0.08 0.06 0.05 
98 0.41 0.88 0.06 0.45 
99 0.08b 0.08 0.06 0.05 
100 0.08b 0.08 0.06 0.05 
 
Supplemental Data Table 1.  Calculated amplification rates using the Po, mean and 
median methods.  High amplification (HA) rate clones chosen for further evaluation are 
shown in bold.   
a
 None of the 12 wells had zero colonies; a minimum estimate was made based on the 
assumption that the thirteenth well would have zero colonies. 
b
 All of the 12 wells had zero colonies; a maximum estimate was made based on the 
assumption that the thirteenth well would have more than zero colonies. 
c
 At least one well had colonies too numerous to count accurately; these wells were 
assigned value of 40 colonies; thus the estimate is a minimum. 
d
 At least 6 wells had colonies too numerous to count accurately; these wells were 
assigned a value of 40 colonies; thus the estimate is a minimum. 
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Fluctuation analysis is a method developed by Luria and Delbruck to calculate an 
inherent mutation rate.  Its implementation allows for differentiating between the rate at 
which a mutation occurs and the frequency of its occurrence.  This method was initially 
applied to studying bacterial mutation rate to confer resistance to phage virus.  We have 
adapted this method to calculate gene amplification rates in Chinese Hamster Ovary 
(CHO) cells.  We specifically utilize the amplifiable marker adenosine deaminase (ADA) 
and the addition of its specific inhibitor deoxycoformycin (dCF) in the presence of excess 
adenosine to select for amplified cells.  We use the number of surviving colonies to 
calculate amplification rates using three methods: the P0 method, mean method, and 
median method.  An explanation of the equations used to calculate this rate is described.  
Analysis of amplification rate data for 100 separate CHO clones shows that there is a 
high fluctuation in the frequency of amplification events which occur in these cells.  
Using this analysis to measure amplification rate may be useful in isolating cell lines 




















The demand for therapeutic proteins has been increasing rapidly over the past decade.  
This class of drugs is produced using mammalian cell lines.  A majority of these proteins 
are currently produced using Chinese hamster ovary (CHO) cells for many reasons.  One 
of the most important reasons is due to the fact that this cell line is known to have an 
unstable genome relative to other candidate cell lines considered for production.  This 
inherent instability allows for the manipulation of their genome for high expression of a 
transgene, making them ideal candidates for biopharmaceutical production (Cacciatore et 
al., 2010).  This inherent instability allows for the isolation of CHO cells with many 
copies of a desired transgene through a phenomenon known as gene amplification.  Gene 
amplification is a term describing the stochastic duplication of a portion of the genome 
during cell mitosis, which can be propagated in subsequent cell divisions.  The ability of 
the CHO cell to undergo this process is taken advantage of to isolate a high producing 
CHO clone with many copies of a desired transgene (Yin et al., 1992). 
 
A gene or genes coding for the therapeutic protein(s) of choice (i.e. monoclonal antibody 
heavy and light chain) are transfected into the CHO host along with a selectable drug-
resistance marker gene. After an initial isolation of transfectants exhibiting a minimal 
level of drug resistance, selection for transfectants that have acquired a modestly higher 
level of resistance by virtue of amplification of the marker gene is carried out. Many 
iterations of this selection process can result in cell clones with a high level of resistance, 
a high level of marker gene expression, and a high number of copies of the marker gene 
which in turn increases the specific productivity of each cell (Wigler et al., 1980).  The 
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popular DHFR/MTX system used for this approach is explained in detail in Chapter 2 
and Chapter 3. 
 
Gene amplified cells are then utilized for production of the therapeutic product because it 
is the most efficient scheme in a fixed size reactor since each cell has its gene copy 
number maximized.  The time needed to isolate these amplified cells is dependent upon 
the rate at which the transfected therapeutic gene amplifies or the mutation rate.  The 
mutation in this case is the DNA duplication of the region containing the marker gene 
(dhfr) and the gene of interest.  The calculation of mutation rate for a specific transfectant 
clone would allow for the estimation of time needed to isolate offspring of that clone 
containing a certain number of copies of the transgene which correlates to higher 
productivities.  In short, a higher mutation rate would allow for quicker isolation of such 












Figure 1-Schematic of CHO gene amplification process.  A CHO cell containing one 
copy of a transgene (black rectangle) integrated into one of its chromosomes has an 
inherent amplification rate (A) which is the probability that it will duplicate in the 
genome in one cell division.  One daughter cell (bottom) is shown to have two copies of 
the transgene after cell division 1 (D1).  Subsequently, the original gene copy amplifies a 
second time so that one daughter cell (bottom) has a total of three gene copies after cell 
division 2 (D2) originating from the 2 gene copy number parent.  After many cell 
divisions (Dn) a cell is isolated with many copies of the transgene and is ultimately used 
to seed a bioreactor to maximize protein productivity expressed by these many transgenes.  
 
When selecting cells of a particular phenotype (eg. colony formation in selective medium 
containing a particular inhibitory drug) one may calculate a mutation rate through the 
observation of the survival phenotype.  Several underlying assumptions for making this 
calculation are that there are no preexisting mutants, no lag in expression of the desired 
mutation being selected for, and no heterogeneity in mutant colonies (Andersson et al., 
2011).  One assumption that is not valid for this analysis is that mutant frequency is a 
perfect reflection of mutation rate.  Despite the fact that the probability of this mutation 
occurring in a given cell division is a small fixed quantity; the time at which it occurs 









amplification rates (A) is assessed using the fluctuation analysis of Luria and Delbrouck 




The L&D analyses were based on the discovery that bacterial mutations can cause 
phenotypical changes such as resistance to certain viruses.  L&D showed that such 
mutations occur independent of the presence of the virus.  Each bacterium has an inherent 
probability that it will mutate from the sensitive phenotype to the resistant phenotype.  
Since this mutation may occur at any time, cultures of resistant bacteria of various sizes 
will exist depending upon what point in time such a mutation has occurred.  Attempts to 
determine the proportion of resistant bacteria to the bacteriophage virus found very large 
variations.  These large fluctuations are a consequence of the varying time in the culture 
where a bacterium mutated to become resistant to the virus and produced daughter cells 
which also exhibit resistance (Luria and Delbruck, 1943).  L&D have formulated two 
different methods for determining mutation rate of a bacterium which is the chance of 
mutation per cell per time unit.  These methods were derived on the assumption that there 
is a small fixed chance per time unit for each bacterium to undergo a mutation.  These 
methods to determine mutation rate can be applied to other mutations as well as to 
eukaryotic cells.  A requirement for such an analysis is that the mutation must be an 
observable property such as resistance to a specific agent.  Similar to the bacterial 
mutation conferring bacteriophage resistance, this probability is captured experimentally 
if the potential gene undergoing mutation were a drug resistance gene.  A random, low 
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probability gene duplication would result in cell survival when subject to an empirically 
determined concentration of the drug that the gene codes resistance for.   
 
It has been previously hypothesized that the rate of gene amplification is dependent upon 
the location of the gene in the genome (Kito et al., 2002).  In the case of producing 
biotherapeutics, genes for these proteins are randomly transfected into various locations 
in the genome and amplified.  Presumably a large fraction of these transfectants have 
integrated the gene of interest and dhfr into a genomic location with an average or below 
average ability to amplify.  However, statistically a small fraction will have integrated 
into genomic locations that are inherently prone to very fast amplification.  In this work 
we aim to develop a method of identifying transfectants with the property of having an 
integrated transgene in a location with a high gene amplification rate.  Determining which 
locations in the genome have high amplification rates and targeting a therapeutic gene to 
that location would prove to be valuable in shortening development time of 
biopharmaceuticals. 
 
Development of an assay to determine amplification rates of various transfectants is not 
trivial.  Such an assay needs to quantify a phenotype brought about through gene 
amplification that can be converted to a rate.  We have developed an assay which 
converts the number of surviving colonies in culture to an amplification rate.  This rate is 
the probability that a transfectant with a gene of interest at a specific genomic location 
will duplicate during a given cell division in an arbitrary time period.  Directly 
correlating the number of surviving colonies to a gene amplification rate requires the 
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derivation of a mathematical model to distinguish colonies arising due to two 
possibilities:  
 
1. An early gene amplification event and many daughter colonies forming from that 
early event 
2. Many gene amplification events occurring later (after many more cell divisions 
have occurred) 
 
Colonies arising due to the latter possibility would represent a high amplification rate 
while colony survival due to the first possibility would not.  The equations used to 
calculate amplification probability per cell division which is directly related to the rate 
have been adapted from L&D. 
 
L&D formulated several methods for determining mutation rate of a bacterium which is 
the chance of mutation per cell per time unit.  In our specific case, the mutation is defined 
as a gene amplification event.  It is known that the probability of this event occurring in a 
given time unit is very small.  Despite this, similar to the bacterial mutation conferring 
bacteriophage resistance, this probability can be captured experimentally since the gene is 
a drug resistance gene.  A low probability duplication event results in cell survival when 
subject to a low concentration of the drug that the gene codes resistance for.  Our 
antagonist in this case is the drug deoxycoformycin (dCF) as opposed to phage in Luria 
and Delbruck’s case.  Our mitigator is a gene amplification event of the gene for 
adenosine deaminase which upon amplification will confer survival in CHO cells in the 
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presence of dCF and excess adenosine (Kaufman et al., 1986).  The ADA/dCF 
amplification protocol is explained in detail by Kaufman et al.  This event is analogous to 
a mutation conferring phage resistance in the case of L&D.  A schematic of each case is 
shown in Figure 2.   
 
 
Figure 2 – Comparison of L&D mutation study vs. CHO gene amplification study.  
Left: If a bacterium undergoes a genetic mutation from the diamond to the square it will 
confer resistance to bacteriophage.  Right:  If the ada gene duplicates it will confer 
resistance to a low concentration of dCF and excess adenosine.  
 
Two sets of equations have been derived in order to determine amplification rate of a 
given CHO clone (Luria and Delbruck, 1943).  One is known as the p0 method and one is 
known as the mean method.  Both derivations are based on a fluctuation analysis, that is, 
the number of surviving colonies will fluctuate based on how early an event occurred.  
The assay is based on seeding transfectants in a specified number of parallel cultures 
CHO Cell Bacterium 
Bacteriophage dCF + excess 
adenosine 
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starting with a very low number of cells from which cell division will originate.  The 
number of surviving colonies is counted and the amplification rate is calculated using 
either the fraction of cultures with no survivors (p0) or the mean of the number of 
surviving colonies in each culture.  The equations for each method applied to our system 




Equation 1:  dNt/dt = Nt  
 
Equation 2:  Nt = N0et 
 
Equation 3:  dm = adtNt    
                                                  
 
Equation 4:  m = a(Nt – N0) 
 




Equation 6:   r = (t-t0) aNt 
 
Equation 7: 1= aC(Nt0 – N0) 
 
Equation 8:  Nt0 = Nte-(t-to) 
 
Equation 9:  t – t0 = ln(NtCa) 
 




m =number of gene amplification events  
a = probability of gene amplification per unit time 
Nt = number of cells in total culture at time t 
N0 = number of cells in total culture at t = 0 
p0 = fraction of cultures with no surviving colonies 
r = average number of resistant cells 
C = number of parallel similar cultures 




L&D assumed the time interval to be in units of division cycles of bacteria (t/ln2) which 
enables the use of equation 1 above.  The integrated form of this result is equation 2.  The 
p0 method is formulated assuming that the number of amplification events in a culture 
(dm) that occur during a time interval dt is equal to the chance of such an event occurring 
(a) multiplied by the number of cells in that culture, which gives rise to Equation 3.                                                                                          
The integrated form of this equation over a given time interval from 0 to t is shown in 
Equation 4.  The number of amplification events in a culture will be small and it is 
assumed will follow a Poisson distribution (P(x) = e-λλx /x!).  Equation 5 shows that P0, 
the fraction of cultures in which no amplification has occurred (no surviving colonies), is 
a function of the number of amplification events (m).  This holds true since P0 represents 
the probability of 0 amplification occurrences across all cultures.  Knowing this value 
which is an observable quantity, we calculate the number of mutations using Equation 5 
(the first term of a Poisson distribution; p(0) = e-λ) and then use this value of m to 
determine the amplification rate (a) in Equation 4.  This development allows us to 
calculate amplification rate as a function of the fraction of cultures with no surviving 
colonies. 
 
The mean method is formulated using Equation 6.  The average (r) number of cells that 
have undergone ADA amplification over a given time interval can be determined by 
calculating the average number of surviving colonies in a culture.   Equation 7 shows that 
the average number of amplification events will equal 1 at a given time set equal to t0.  
Since the growth rate of cells (dNt/dt) is proportional to the number of cells present, the 
number of cells present when the first amplification event occurs can be determined by 
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Equation 8.  Substituting for Nt0 in Equation 7 and knowing that the initial number of 
seeded cells (N0) is negligible, one arrives at Equation 9.  Combination of Equation 6 and 
Equation 9 results in Equation 10 which relates average number of amplification events 
across all cultures (r) to amplification rate (a).  Equation 10 is the final equation utilized.  
This equation allows us to calculate amplification rate as a function of the observed mean 
of surviving colonies in parallel cultures. 
 
A third equation (Equation 11) has also been implemented in calculating amplification 
rate that was developed by Lea and Coulson (L&C) known as the median method.  This 
equation is solved for m to determine the number of mutations as a function of the 
median number of surviving colonies across all cultures (Lea and Coulson, 1949).  After 
solving for the number of mutations per culture (Equation 11), one can use Equation 4 
above to solve for amplification rate (a). 
Median Method 
Equation 11:  (R0/m) – log m = 1.24   
 
R0 = median value of resistant colonies across all cultures 
m = number of mutations per culture 
 
Specifically, our assay measures gene amplification by utilizing the drug marker 
adenosine deaminase.  Adenosine deaminase is an enzyme which deaminates adenosine 
in the cell.  Excess adenosine is toxic to the cell and the action of this enzyme prevents 
cell death by reducing intracellular concentration of adenosine.  Deoxycoformycin (dCF) 
is a specific inhibitor of the ADA enzyme. Cells that have undergone gene amplification 
at the site of the ADA gene (thus increasing its gene copy number) will be able to survive 
in the presence of excess adenosine and dCF (Kaufman et al., 1986).  In comparison to 
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L&D, CHO cells are analogous to bacterial cells, the presence of 0.5 µM dCF and 1.1 
mM excess adenosine are analogous to the presence of bacteriophage virus, and an 
amplification of the ADA gene is analogous to a genetic mutation causing resistance to 
bacteriophage.  In both cases, the observable phenotype is cell survival.  We utilized the 
methods employed by L&D and L&C to calculate amplification rates on 100 different 
clones who have presumably integrated a copy of ADA at different genomic loci.  The 
observable frequency (number of colonies) in 12 separate cultures was used to calculate 




The detailed methods used for challenging each CHO clone and observing mutant or 
“amplificant” frequency is explained in our previous work from Chapter 3.  Upon 
mimicking a fluctuation analysis we made several observations about the resulting data 
which can be seen in Table 1.  Rates were calculated using all three of the 
aforementioned methods and the total average was taken.  The calculated amplification 
rates are reported as duplication events per cell generation x 106.  The rates had a wide 
variation ranging from 0.05 to 9.17.  In the case of clone 97, each of the 12 cultures failed 
to yield any colonies (amplificant frequency of zero).  This represents the minimum 
extreme in which the clone has zero chance of undergoing a gene amplification event.  In 
the case of clone 75, all cultures had too many colonies to accurately count, so the value 
was estimated to be 40 (the largest number that can be comfortably counted given the 
size of the culture dishes).  This represents the maximum extreme in which the clone 
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presumably has the ability to amplify that particular region of DNA at the highest rate 
among the 100 that we tested.   
 
A more detailed look at the data is shown where the raw numbers are listed for clone 4 
out of 100 in Table 1.  The number of counted amplificant colonies is represented for 
each culture well (C1 through C12).  The value of 0.88 for the standard deviation divided 
by the mean confirms that there are indeed high fluctuations of amplificant frequency for 
this clone.  A high deviation among cultures also exists among most of the 100 clones 
tested.  This example further illustrates the need to apply these mathematical equations to 
correct for mutant frequency in determining rates.  Another observation for this clone 
shows that there is good agreement between the determined A using each of the three 
methods.  This tends to be true for lower calculated A values, but there tends to be poor 
agreement amongst the three methods for those with high calculated A values.  This can 
be attributed to the inherent differences in the 3 methods since p0 frequency is totally 
independent of mean and median, and mean and median can also be quite different for 































Table 1 – Raw colony count data for clone 4 used to calculate amplification rate.  
Calculations are based on 12 parallel cultures (C1-C12).  Rates calculated using the p0, 
mean, and median method are bolded.  The average of each of these values is shown as 
total average (Totavg).  Standard deviation (std) and standard deviation relative to the 
mean (std/mean) are also tabulated.  
 
 
Discussion       
 
In this work we sought to apply fluctuation analysis which has been derived and 
successfully applied to bacterial mutations in previous works.  We apply this analysis to a 
scenario in which identifying high mutation or amplification rates could be beneficial to 
the more efficient production of important therapeutic or diagnostic proteins.  We 
developed a specific assay analogous to L&D’s analysis of bacterial mutation rate against 
bacteriophage to assess how quickly a marker gene in a given genomic location will 
amplify over the period of several cell divisions.  Isolation of a CHO clone with a high 
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amplification rate would presumably be an advantage over a clone with a low or average 
rate since this theoretically would result in higher protein production in a shorter amount 
of time.   
 
After applying this analysis to our system using a marker gene transfected into 100 CHO 
host cells at various genomic locations and challenging with a specific ADA inhibitor, we 
found a wide range of amplification rates using 3 different derived mathematical methods.  
Since presumably the chromosomal location at which this marker gene integrated is the 
only variable in this process, this wide range agrees with previous results which infer that 
chromosomal location is a major determinant of amplification rate.  This may be due to 
varying instability throughout various regions of the genome due to chromatin structure, 
surrounding genes, promoters and regulatory sequences, or proximity to centromeres.  
This “position effect” may be taken advantage of through the development of a cell line 
with the ability to integrate a transgene at that particular location for quick amplification 
and subsequent protein production.  A scheme involving site-specific recombination to 
pursue this is discussed in previous work in Chapter 3.  
 
The variability among specific methods (p0, mean, and median) is attributed to the 
amplificant frequency distributions among each clone.  For example, a clone with all 12 
parallel cultures containing amplificants but each containing a low number of these 
amplificants will correspond to a high rate using the p0 method but a low rate using the 
median or mean method.  In another example, a clone with most cultures containing zero 
amplificants but a low fraction of the cultures with many amplificants will correspond to 
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a low rate using the p0 or median method but a high rate using the mean method.  There is 
no direct answer as to which method is the best for calculating rates as each is 
mathematically derived in a logical fashion.  However, it may be more appropriate to use 
one method over the other depending on the distribution of amplificant frequency 
observed among parallel cultures. 
 
In conclusion, we show that fluctuation analysis can be applied to more sophisticated 
biological systems involving CHO cells undergoing transgene amplification and that this 
method has the potential to engineer cell lines for faster production of therapeutic 
proteins.  Furthermore, such a method may be applied to other sophisticated systems in 
which the rate of a biologically important mutation is desired as opposed to simply the 
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Site-specific recombination (SSR) is a technology that can be utilized to integrate a DNA 
sequence into a specified location in the genome.  We have developed a cell line which 
contains several thousand recognition sequences (attP sites) for the enzyme φC31 
integrase.  Our goal is integrate many copies of a transgene into these locations.  Despite 
the generation of many genomic attP sites, subsequent integration of a plasmid containing 
the gene for dihydrofolate reductase (dhfr) and an attB recognition sequence was 
inefficient.  Using calcium phosphate-DNA co-precipitation to co-transfect this plasmid 
and a plasmid coding for φC31 recombinase we integrated about 25 copies of the gene.  
We attempted to improve upon this modest recombination efficiency by increasing the 
concentration of the attB plasmid through polyoma virus large T-antigen replication but 
saw no improvement.  We found that the addition of a specific 5 base pair flank on either 
end of both the attP and attB site improved recombination efficiency by over 20 fold as 
determined by an in vitro recombination assay.  We plan to select for DNA sequence 
flanks that promote more efficient recombination and incorporate these sequences into 
cell lines with many recombination sites.  This may allow for massive integration of a 
transgene for a therapeutic protein and decrease the time needed to isolate a highly 














The first step for producing biopharmaceutical drug candidates such as monoclonal 
antibodies is the permanent transfection of its DNA sequence into a host cell line such as 
Chinese hamster ovary (CHO) cells.  After isolation of transfectants, a lengthy process 
known as gene amplification is utilized to increase the gene copy number, therefore 
increasing overall expression and protein secretion per cell.  This is required since 
random transfection by various methods (calcium-phosphate co-precipitation, 
electroporation, liposomes) result in transfectants with 1-5 copies of the gene integrated, 
some of which are in poor expression locations (Zhou et al., 2010).  In previous work we 
utilized site-specific recombination using φC31 integrase to target a transgene to one 
specific genomic location which was deemed to be highly amplifiable to decrease the 
time necessary to isolate a high producing cell line.  In this work we aim to extend the 
use of site-specific recombination technology to test whether many copies of a transgene 
can be integrated into the genome in one single recombination reaction, therefore 
abrogating the need for lengthy MTX amplification.   
Site-specific recombination (SSR) is a novel method that has been investigated for the 
precise integration of therapeutic transgenes into host cell lines for production.  This 
process is catalyzed by enzymes known as site-specific recombinases (Calos, 2006).  This 
method allows one to integrate a transgene into the genome at a specific location which 
contains a recognition sequence for recombination into that site.  This also relies on the 
transgene being coupled to another recognition sequence and the presence of a 
recombinase to bind each substrate and catalyze the recombination of the transgene into 
the genome.  This can be thought of as a three bodied intermolecular reaction.  One 
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molecule is the incoming DNA containing one SSR recognition sequence and the 
therapeutic transgene.  The second molecule is the chromosome containing the other SSR 
recognition sequence.  The third is the SSR enzyme that catalyzes recombination between 
the two sequences.  In this work we aim to maximize all three components.  First we aim 
to increase the number of genomic recombination sequences.  Once we have maximized 
this component we switch to maximizing the number of incoming plasmids containing 
the other recombination site and our transgene.  Finally, we focus on improving the 
efficacy of the site-specific recombinase.  Our overall goal is to drive the reaction 
forward so that a high number of transgenes can be integrated into the genome in one 
process.    
 
One recombination system we used was the cre/lox system which uses cre recombinase 
as the enzyme and DNA recognition sequences known as loxP sites (Hoess and Abremski, 
1985).  This system was initially chosen among other recombinase systems such as the 
flp/FRT system because it has been previously used in other studies and shows that its 
recombination efficiency is better than other recombinases (Raymond and Soriano, 2007).  
Initially, we sought to use recombinase mediated cassette exchange (RMCE) for the 
purpose of integrating a transgene between two loxP sequences at many genomic sites 
which we amplify using MTX amplification.  This scheme first involved permanently 
transfecting a construct containing the endogeneous dhfr gene with exon 2 flanked by 
two loxP sites.  Next, we aimed to amplify this construct using MTX amplification to 
many copies so that targeting to these many locations can occur with a subsequent co-
transfection of cre recombinase vector and an incoming plasmid with the same loxP sites 
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flanking a hygromycin resistance gene.  Despite high efficiencies associated with the cre 
recombinase system, recognition sequences that are present after integration can act as 
substrates to promote gene excision in the presence of cre recombinase.  Due to this fact, 
we also used another recombination system known as the φC31 system since transgene 
integration cannot be reversibly excised (Thyagarajan et al., 2001a).   
Unlike the cre recombinase system, upon site-specific integration of the transgene the 
recombined substrates (attL and attR sites) are not substrates for excision.  Similarly to 
the cre system mentioned above, φC31 recognition sequences (attP sites) are transfected 
into the CHO genome and amplified to many copies for subsequent targeting of a 
transgene to those many sites.  A schematic of each process can be seen in Figure 1 and 
Figure 2.   
 
Figure 1 – Schematic of cre/lox recombination system.  A construct containing the full 
dhfr gene (only first three exons shown) with lox sites L1 and 2L flanking exon 2.  In the 
presence of cre recombinase the L1 and 2L sites will interact with the incoming L1 and 
2L sites respectively which flank the hyg gene.  The result of this recombinase mediated 
cassette exchange (RMCE) is the hyg gene integrated into the genome at the previous 
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Figure 2 -  Schematic of φC31 integrase system.  An attP site in the genome interacts 
with an attB site on the incoming dhfr/G.O.I. (dhfr marker gene with a gene of interest) 
plasmid in the presence of φC31 integrase.   123 copies of this construct exist after 
amplification using dCF (deoxycoformycin) and excess adenosine.  This recombination 
results in dhfr and the G.O.I. being integrated into the genome and the creation of hybrid 
attL and attR sites.  An attL site is a hybrid between the upstream portion of attP and the 
downstream portion of attB since the DNA is cleaved in the center of this sequence.  An 
attR site is a hybrid between the upstream portion of attB and the downstream portion of 
attP.  ADA is an adenosine deaminase amplifiable marker and neo is a neomycin 
resistance gene used for selection.  Ideally recombination takes place at all 123 sites to 
yield 123 copies of dhfr and the G.O.I. 
 
 
We ultimately moved forward using the φC31 integrase system due to our observations 
that cre recombinase was causing unwanted excision of our integrated transgenes to occur.  
The φC31 enzyme, like many recombinases, is inefficient in performing recombination; 
however we describe methods below aimed at improving this recombination.  In moving 
forward with the φC31 integrase system to integrate a high number of copies into many 
locations, there are 3 parameters we focused on to optimize this process. 
First it is obvious that maximizing the number of attP sites for integration should increase 
the probability of targeting many transgenes into the genome.  Alternatively, increasing 
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both the amount of attB sites and φC31 integrase efficacy could drive the reaction in vivo.  
Here we describe how we increase each of these parameters which in turn may prove to 
drive this recombination into many attP sites. 
Increasing attP concentration 
Since an attP site is a specific 39 base pair sequence (Zhou et al., 2010), one cannot 
expect it to be naturally occurring in the genome.  Previous studies have shown that 
pseudo attP sites exist in the CHO cell genome and can act as a substrate for φC31 
integrase with as little as 44% sequence similarity to the wild type attP site (Ginsburg and 
Calos, 2005).  Despite this finding, site-specific recombination may not be as efficient in 
these sites compared to the wild type.   An engineered cell line containing many wild 
type attP recognition sites may prove to be useful to maximizing SSR of a certain 
therapeutic gene.  We describe two methods of increasing the amount of substrate attP 
sites in the CHO genome.  The first method of increasing genomic attP substrate for 
φC31 recombinase is pre-amplifying the cell using an amplifiable marker linked to attP 
sites.  Adenosine deaminase also known as ADA was chosen for this purpose.  Adenosine 
deaminase is an enzyme which deaminates adenosine in the cell.  Excess adenosine is 
toxic to the cell and the action of this enzyme prevents cell death by reducing 
intracellular concentration of adenosine.  Deoxycoformycin (dCF) is a specific inhibitor 
of the ADA enzyme.  Cells that have undergone gene amplification at the site of the 
ADA gene (thus increasing its gene copy number) will be able to survive in the presence 
of excess adenosine and dCF (Kaufman et al., 1986).  We have linked an attP site to 
ADA and amplified cells to contain 123 copies of attP sites (Figure 2).   
 104
A second method used to increase attP substrate was to create a concatemer of attP sites 
on one single vector.  This was performed through subsequent digestion and ligation of 
attP sequence to create a concatemer of 64 attP sites (see Methods).  This effectively 
increases the attP immediately following transfection of the construct into cells.  
Furthermore, by coupling this method with dCF amplification one can increase the 
number of attP recognition sites significantly.  An overview of this process is shown in 
Figure 3.  Ultimately, the copy number of genomic attP sites was maximized by 
combining the two aforementioned methods.   
ΦC31
Integrase
exons 2-6 G.O.I. attRdhfr Exon 1attL




Figure 3 – Schematic of amplified attP genomic DNA.  The small rectangles represent 
a concatemer of 64 attP sites.  One of these sites will interact with the incoming attB site 
on the dhfr/G.O.I. plasmid to integrate this sequence into the genome in the presence of 
φC31 integrase.  The remaining attP sites remain intact for additional recombination 





Increasing attB concentration 
Another way to maximize recombination into these many attP sites is to increase the 
amount of incoming plasmid containing attB sites and the transgene of interest.  Unlike 
the case for the attP site, we cannot create concatemers of attB sites on each incoming 
plasmid since upon recombination, original attP and attB sites will be within close 
proximity of each other.  This may cause intrachromosomal DNA deletions between 
these sequences and excise the transgene of interest in a similar way as the cre/lox system.  
Two other methods were employed for this purpose. 
The first method is to improve the delivery of this plasmid into host cells for 
recombination to occur.  When co-transfecting the attB/G.O.I. plasmid with the plasmid 
coding for φC31 integrase, any standard method of DNA delivery may be used.  In an 
attempt to maximize the amount of attB we conducted experiments using both 
Lipofectamine 2000 and calcium phosphate DNA co-precipitation.  Presumably, an 
effective delivery method will increase the intracellular concentration of the φC31 
expression plasmid also. 
A more novel method that we employed is the use of a viral replication mechanism to 
exponentially increase the target attB/G.O.I. plasmid.  This method has been successfully 
used in CHO cells expressing a polyoma large T-antigen which binds a polyoma origin of 
replication inserted into the attB/G.O.I. plasmid.  This was shown to cause a high degree 
of replication (La Bella and Ozer, 1985).   
Increasing φC31 Integration Efficiency 
As mentioned earlier, the amount of intracellular φC31 expression vector may be 
increased by optimizing the DNA delivery method.  It may also be possible to modify the 
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φC31 integrase to maximize recombination efficiency into many genomic sites.   There 
are two methods we utilize in an attempt to improve the recombination efficiency of the 
enzyme.  The first is linking zinc finger proteins onto both the amino and carboxyl 
termini of the integrase and in parallel adding zinc finger binding sites (ZBS) flanking the 
attP and attB DNA.  This strategy of using different zinc finger chimeras to improve 
protein binding has been studied extensively (Akopian et al., 2003).  Another method we 
explored was to create a mutant library of φC31 integrase enzymes and assess which 
performed recombination the best.  In performing these experiments, an in vitro assay 




Plasmids pDS1, pHygLox, and pCre were obtained from Shulian Shang.  Plasmid pDS1 
developed by Shulian Shang contains a dhfr minigene with two inverted and heterologous 
loxP sequences flanking exon 2 (L1 and 2L).  L1 is the wild type recognition sequence 
and 2L is the inverted sequence of mutant lox site lox72 (Albert et al., 1995).  The 
sequence of these 34 bp recognition sequences are as follows:  L1: 5’-
ATAACTTCGTATAGCATACATTATACGAAGTTAT-3’; 2L:  5’-
TACCGTTCGTATAATGTATGCTATACGAACGGTA-3’.   Plasmid pHygLox 
contained a hygromycin resistance gene (hyg) flanked by these same two inverted loxP 
sequences.  Plasmid pCre coded for the enzyme cre recombinase which catalyzed site-
specific recombination.  Linearized plasmid pDS1 was transfected into host DG44 cells 
by electroporation.  The stable cell line containing this endogeneous dhfr was subject to 
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MTX amplification to achieve high copy number of the transgene using the following 
stepwise concentrations: 10nM, 20nM, 50nM, 200nM, 1µM, 5µM, 20µM, 100µM, 200 
µM.  Plasmids pHygLox and pCre were co-transfected using Lipofectamine 2000 
(Invitrogen) according to manufacturer’s instructions.  Cells that successfully received 
the hyg gene were selected with 200µg/mL hygromycin.  Relative copy number of hyg 
and dhfr were measured using real-time PCR on an Applied BioSystems 700 
thermocycler.  The endogeneous gene for adenine phosphoribosyltransferase (APRT) was 
used as an internal standard.  The following primers were used:  Dhfr exon 2:  Left: 5’-
CCATGTTAACGCAGTGTTTCTC-3’; Right: 5’-CCCACGGGAGACTTCGCACT-3’; 
Hyg:  Left: 5’-TACATCAATGGGCGTGGATA-3’; Right: 5’-
GATGTTGGCGACCTCGTATT-3’; aprt: Left: 5’-CCTGGAGGCAGGACTGTAAG-
3’; Right: 5’- GGCAGCCTGGTAAGTGAAAG-3’.   
Plasmid Construction (φC31 experiments) 
The adenosine deaminase gene driven by a CMV promoter was isolated by ApaLI 
digestion from plasmid pCMVADA (American Type Culture Collection).  The insert was 
ligated into a unique ApaLI site in the vector pEGFP-C3 (Clontech: GenBank Accession 
# U57607) to create vector pADAGFP containing kanamycin/neomycin resistance and 
the adenosine deaminase gene.  A synthetic attP double stranded oligomer was inserted in 
between unique XhoI and SalI restriction sites to create the vector pKAP1 containing a 
single attP site.  The components of this plasmid are shown as the top linear construct 
depicted in Figure 2.    Adjacent attP sites were added to the plasmid in a geometric 
fashion.  Vector pKAP1 was digested with SalI and BamHI located downstream from 
SalI.  The single attP site was digested from vector pKAP1 between XhoI and BamHI 
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sites and inserted into the previously plasmid digested with SalI and BamHI.  This 
ligation was permitted due to XhoI and SalI having matching overhangs.  The result was 
a plasmid containing two attP sites (pKAP2).  The following process was repeated since 
all three restriction sites were reconstituted.  The final plasmid contains 64 attP sites 
(pKAP64).  This method is outlined in Figure 4. 
 
Figure 4 – Method for creating attP concatemers.  A plasmid containing one attP site 
flanked by XhoI and SalI restriction sites and a BamHI restriction site downstream of 
SalI was used as the starting DNA.  This plasmid was digested in two separate reactions.  
One reaction digested the plasmid with XhoI and BamHI to isolate the attP site.  The 
other reaction digested the plasmid with SalI and BamHI.  The attP insert was then 
ligated into the previously digested plasmid at the SalI and BamHI sticky ends.  This is 
possible since SalI and XhoI share the same 4 base pair overhang upon digestion.  The 
result is a plasmid containing two attP inserts with each of the three original restriction 
sites reconstituted for further digestion.  This process is repeated to add attP sites in a 
geometric fashion (2 to 4 to 8, etc.).  The final plasmid contained a concatemer of 64 attP 
sites and was used for subsequent transfection into host DG44 cells. 
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Plasmid pPGKPhiC31obpA was obtained from Addgene (#13795) (Raymond and 
Soriano, 2007) and contains the mouse-codon optimized φC31 integrase gene driven by 
the PGK promoter.  The plasmid pdchip11 contains a full minigene for dihydrofolate 
reductase (dhfr).  A synthetic attB site with XmaI sticky ends was ligated into a unique 
XmaI restriction site upstream of the dhfr gene creating the plasmid pBE16.  The 




DG44 cells were transfected with pKAP64 and selected for 3 weeks in 800 µg/mL G418 
(Geneticin®).  Surviving colonies were pooled and subject to dCF amplification utilizing 
the ADA marker.  Stepwise dCF amplification was performed by adding incremental 
amounts of dCF and selecting at each stage for two weeks.  These final drug 
concentrations were 0.5, 1, 5, 10, 20, 50, and 100uM.  Recombination reactions were 
performed on 1 million cells by co-transfection with pPGKPhiC31obpA and pBE16 
using either Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
instructions or calcium phosphate DNA co-precipitation using standard protocols from 
Murray (Murray, 1991).  Cells were selected in purine and thymidine free medium 
(“PTF” medium: Alpha MEM without nucleosides and deoxynucleosides, Thermo 
Fisher) for 3 weeks.  Colonies were fixed with 3.7% formaldehyde and stained with 




φC31 Recombination Reactions 
Recombination reactions were performed by co-transfecting plasmid pBE16 and plasmid 
pPhiC31obP in a 1:4 molar ratio using Lipofectamine 2000 or calcium phosphate DNA 
co-precipitation.  After 48 hours cells were transferred to PTF medium at a dilution of 
1:10.  Cells were selected for three weeks for stable dhfr integration.  Surviving colonies 
were pooled and grown to confluency.  Genomic DNA was isolated from the resulting 
cells using the GenElute™ Mammalian Genomic DNA Miniprep Kit (Sigma Aldrich).   
Quantitative Real-Time PCR 
Real-time quantitative PCR was performed using the Applied Biosystems Thermocycler 
7300 and SYBR green as a reporter.  The gene for glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as an internal standard to determine copy number of 
genes in amplified cell lines using the ∆∆Ct method.  To determine the number of attP 
sites in the genome the following primers were used: 
 Left: 5’-CGACAACCACTACCTGAGCA - 3’; Right:  5’-
CCAGTTGGGGCTCGAGAT–3’. 
 To determine the number of subsequently integrated dhfr minigenes into the genome by 
both random integration and φC31 recombination the following primers were used: Left: 
5’ – CTGGCCAATGCTCAGGTACT – 3’; Right:  5’ - GGACTTTGCTCCCAGCTAGA 
– 3’.  The primers used for the gapdh internal standard were:  Left: 5’ – 






The details of the protocols associated with modifying the attB/G.O.I. plasmid and 
current CHO host for self replication using polyoma Large T-antigen can be seen in the 
Master’s thesis of Mrinalini Gururaj. 
Improving φC31 Integrase Efficiency 
The details of the protocols associated with improving the φC31 integrase using both 
zinc-finger chimeras and directed evolution are discussed in detail in the Master’s thesis 
of Laurens Moore van Tienen. 
 
Results 
Cre/Lox site specific recombination 
 
A cell line was successfully isolated containing a dhfr minigene with exon 2 flanked by 
inverted heterologous lox sites (L1 and 2L) by selection in PTF medium (from Shulian 
Shang).   This cell line was taken through several rounds of MTX amplification up to 
200µM and dhfr copy number was measured to be 115 with respect to the aprt standard 
(2 copies in DG44) and was named JC200.  Next we sought to integrate the hyg 
resistance gene into many of the exon 2 locations via cre/lox mediated RMCE (Figure 1).  
After performing the recombination reaction (co-transfection of a cre recombinase 
expressing plasmid and the hyg plasmid flanked by lox sites) in cell line JC200 and 
selecting for hygromycin resistance, we isolated genomic DNA from the transfectant pool 
and measured hyg copy number along with exon 2 copy number to assess hygromycin 
gain against exon 2 copy loss.  A large gain in hyg coupled with a large loss of exon 2 in 
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the genomic DNA would be indicative of successful integration of the hyg transgene into 
many loci via RMCE.   
 
We observed that during the first few days of co-transfection of pCre (cre recombinase 
expressing plasmid) and pHygLox (plasmid containing the hygromycin gene flanked by 
lox sites) there was considerable cell death which is uncommon at this stage during 
transfection.  After isolation of genomic DNA from transfectants we measured a very 
large decrease in exon 2 copy number coupled with only a very modest number of 
integrated hyg transgenes.  Control transfections into JC200 cells were performed using 
only the pCre plasmid or only the pHygLox plasmid.  We observed similar cell death 
during the first few days post-transfection using only pCre.  We also measured similar 
hyg gene levels in transfectants only transfected with pHygLox which randomly 
integrated into the genome.  These results were indicative of a massive excision of exon 2 
and genomic DNA between amplified identical lox sites without the expected coupled 
massive integration of hyg into the previous locations of exon 2 via RMCE.  This massive 
excision was seen from a sharp decrease in the real time PCR signal of the cells that have 
been subject to the co-transfection compared to the original cells.  The cycle threshold 
(Ct) for detecting PCR product of exon 2 went from 16 in the original cells to 23 in the 
recombined cells.  This corresponds to a 128 fold decrease in exon 2 presence which 
implies that almost all exon 2 sequences were excised. 
In order to avoid the excision reaction of exon 2 we flanked that sequence with inverted 
loxP sites which prevents cre from catalyzing excision.  Despite this, we were 
implementing this reaction in a cell containing 115 copies of this pair of loxP sites.  Our 
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result was most likely due to intrachromosomal excision between alike L1 sites or alike 
2L sites.  Since identical sites (L1 or 2L) were initially amplified in the genome of these 
cells, there should be on the order of 105 base pairs between recognition sites (Hamlin, 
1992)   Hamlin found this base pair distance to be the size of a typical amplicon while 
studying gene amplification of the dhfr gene in CHO cells.  We had assumed that this 
distance would be too large for cre recombinase to act in a cis manner for the excision of 
the sequence between two identical sites.  Based on this result, this assumption was 
incorrect: this intrachromosomal recombination reaction apparently dominated over the 
trans integration reaction via RMCE.  This is most likely due to identical sites being in 
close proximity because of the compact structure of DNA in chromatin.  
 
φC31 Recombination in an Amplified attP Cell Line (DG44-PP) 
 
After our results using the cre/lox recombination system indicated cre-mediated massive 
excision, we utilized the irreversible φC31 integrase system.  This was an improvement 
over the cre/lox system since we used only attP sites to populate the host genome and 
excision cannot occur between two of these sites (Thyagarajan et al., 2001b).  
Furthermore, upon integration using an attB bearing plasmid, hybrid attL and attR sites 
are formed which are not substrates for subsequent excision in the presence of φC31 
integrase.  AttB sites were not chosen to be the sequence present in many copies in the 
genome since it has been shown that pseudo attP sites already exist in the CHO genome, 
whereas pseudo attB do not (Chalberg et al., 2006).  This study shows that as low as a 
44% sequence similarity to the wild-type attP sequence can result in recombination with 
an attB site in the presence of φC31 integrase.  After transfection of plasmid pKAP64 
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(see Methods) into DG44 cells we isolated the host cell line DG44-PP which contains at 
least one stably integrated concatemer of 64 adjacent attP sites.  This cell line was then 
subject to dCF amplification for resistance up to 200 µM and the genomic DNA from this 
pool of cells was isolated to measure the copy number of this construct.  The average 
copy number of the pKAP64 construct from this pool was found to be 123.  The 
calculated copy number of attP was then multiplied by 64 since each transfected cassette 
contained 64 attP sites yielding a total of 7872 attP sites available for subsequent targeted 
integration of a transgene comprised of the attB/G.O.I. plasmid.  Once this cell line was 
established we performed co-transfections of both the attB/G.O.I. plasmid (pBE16) and 
the plasmid coding for φC31 integrase (pPGKphiC31obpA).   
First we observed the number of surviving colonies in purine and thymidine free (PTF) 
medium for both this co-transfection and a control transfection with plasmid pBE16 
containing an attB site and the full dhfr minigene.  Both are expected to result in colony 
formation since both random integration and φC31 directed integration into one of many 
attP sites will both yield dhfr expression and survival in this medium.  After transfection 
of 5 x 105 cells and splitting to a 100mm dish and selection in –PTF medium for 3 weeks 
the resulting stained colonies are shown in Figure 5 (A).  We see a much higher density 
of colonies in the co-transfection with φC31 indicative of more cells stably integrating 
and expressing dhfr.  Based on this result we repeated these transfections and began 
selection immediately in PTF medium supplemented with 10nM and 20nM MTX 
mimicking the early levels of MTX amplification.  We hypothesize that since more cells 
integrated dhfr, a fraction of them may have integrated multiple copies.  Figure 5 (B and 
C) show clearly that many more colonies survived when φC31 was included in the 
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transfection when challenged at these MTX levels.  At the 20nM MTX level, there were 
no survivors at all for the control transfection experiment (only pBE16).  MTX 
concentrations of 50nM and higher were tested similarly, however there were no apparent 
survivors in either case (not shown).  Gene copy numbers at these levels of resistance 
usually correspond to only modest numbers (less than 10).  Colony formation at much 
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Figure 5 – Stained Transfectants with and without φC31 integrase vector.  A)  
DG44-PP cells transfected with either the incoming dhfr/G.O.I. plasmid named the attB 
plasmid for short or the attB plasmid with the vector coding for φC31 integrase.  
Transfectants were selected for in PTF medium.  B)  DG44-PP cells were transfected in 
the same way as in A.  Transfectants were selected for in PTF medium supplemented 
with 10nM MTX.  C)  DG44-PP cells were transfected in the same way as in A.  
Transfectants were selected for in PTF medium supplemented with 20nM MTX.  In all 
cases cells were selected for 3 weeks and colonies fixed with 3.7% formaldehyde and 
stained with crystal violet.   
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To assess copy number in these cells we used real-time PCR.   To confirm that our 
primers (see Methods) were amplifying the correct sized sequence we performed 
endpoint PCR and ran the PCR products on a 0.8% agarose gel stained with ethidium 
bromide.  Several controls that were included were DG44 (CHO dhfr double deletion 
mutant) genomic DNA, and each transfection (with and without φC31 integrase) 
performed using DG44 as the host as opposed to DG44-PP cells.  This result is shown in 
Figure 6.  We observed the correct sized band for dhfr.  The signal of dhfr was not 
affected by using 4µg, a high amount (H) instead of 1µg, a low amount (L) of input DNA 
used for each transfection.  The gel did not show a stark difference in signal between 
cells transfected with and without the φC31 plasmid indicative of similar copy numbers 
being present in each pool.   
 
Figure 6 – Endpoint PCR of Genomic DNA from Transfectant Pools.  PCR products 
for GAPDH (G) and dhfr (D) are shown using genomic DNA from different pooled 
transfectants as template.  A no template control (NTC) is run in the first two lanes.  
DG44 is used as a negative control since it is deficient in both copies of dhfr and is run in 
the next two lanes.  The next two lanes are from DG44 cells transfected with 4µg (high 
amount) of attB plasmid (DB-H).  The next lanes are DG44 cells transfected with 1 µg 
(low amount) of attB plasmid with φC31 plasmid (DΦB-L).  The first two lanes in the 
bottom half of the gel are from DG44 cells transfected with 4 µg of attB plasmid with 
φC31 plasmid (DΦB-H).  The next two lanes are from DG44-PP cells transfected with 4 
µg of attB plasmid (PPB-H).  The last two lanes are from DG44-PP cells transfected with 
4 µg attB plasmid with φC31.  The ladder used is HyperLadder II from BioLine. 
 
We followed this experiment up with real time PCR using GAPDH as a standard to 
determine relative copy number.  The values for each transfection are relative to DG44 
cells transfected with 4µg pBE16 which mimics a standard method to randomly integrate 
a transgene.  These results are shown in Figure 7.  
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Figure 7 – Relative dhfr copy number measured using real time PCR.  Copy numbers 
for integrated dhfr are shown relative to transfecting DG44 cells with the attB plasmid 
only (DB-H) shown as the first bar.  Values were calculated using GAPDH as an internal 
standard.  Abbreviations are explained in the legend to Figure 6. 
 
Consistent with the gel, we observe similar copy numbers of dhfr relative to the control, 
and all levels are very modest.  Despite more survivors with modest increases in dfhr 
copy number as seen in Figure 6, these pools of cells showed no improvement with 
respect to the controls.  We surmised two ways to improve this system.  The first was to 
change transfection methods since a different way of delivering DNA may be more 
amenable to site-specific recombination into many sites even if it hasn’t proven to be 
superior for random integration.  The second modification we made was to isolate 
individual clones instead of measuring the pool of cells to see if there was a high 
variation in dhfr copy number.  Perhaps we would be able to find one outlying clone 
containing many integrated dhfr copies.  
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We repeated the experiments using calcium phosphate DNA co-precipitation.  This 
method has already been proven to be able to successfully deliver large amounts of DNA 
into a variety of cell hosts (Murray, 1991).  We transfected pBE16 into DG44-PP cells 
both with (site-specific integration) and without (random integration) the φC31 integrase 
gene.  We once again measured integrated dhfr copy number using GAPDH as an 
internal standard relative to UA41 cells which have been previously isolated and contain 
only 1 endogeneous copy of dhfr.  The results are shown in Table 1.  The most important 
result is that calcium phosphate DNA co-precipitation yields about a 5 fold greater 
efficiency of site-specific recombination than Lipofectamine 2000.  This occurs despite 
the result that Lipofectamine 2000 is more efficient for delivering DNA that is randomly 
integrated into the genome.   
 
Recombination Reagent Copy no.  
Site-specific Lipofectamine   5.2 
Site-specific Ca3(PO4)2 25.4 
Random Lipofectamine 19.4 
Random Ca3(PO4)2   1.1 
 
Table 1 – Dhfr copy number across different transfection conditions.  Copy number 
was measured using real-time PCR and GAPDH as an internal standard.  Copy numbers 
are absolute relative to the signal provided by UA41 cells which contain one allele of 
dhfr.  The highest value obtained using calcium phosphate DNA co-precipitation 
(Ca3(PO4)2) and transfecting with φC31 integrase vector (site-specific) is in bold.   
 
After taking measurements on transfectant pools resulting from the calcium phosphate 
method, we isolated individual colonies that survived selection in PTF medium 
supplemented with 20nM MTX.  This ensured that we were isolating only those that were 
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able to overcome the MTX by virtue of an increased copy number of dhfr.  We measured 
dhfr copy number for 6 individual clones and two pools of transfectants relative to the 
control transfection of our cell line without φC31 integrase.  These values are shown in 
Figure 8.  Clone 1 had the highest relative copy number of about 5 which was an 
improvement over the average copy number of the two transfectant pools.  Although this 
is an improvement over random transfection, it is still very low considering the number 
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Figure 8 – Relative dhfr copy number using calcium phosphate DNA co-
precipitation.  Measurements using real time PCR on two different pools and 6 clones of 
transfectants initially resistant to 20nM MTX are shown.  Values are relative to a 







Polyoma Large T-Antigen Mediated attB Plasmid Replication 
 
Our previous results show that by increasing the number of genomic substrates (attP 
sites) to a very high level we were unable to achieve a large improvement over randomly 
transfecting transgenes into host CHO cells in terms of the number of transgenes 
integrated.  Therefore, using the system as currently developed, one would still need to 
perform MTX amplification to further amplify the dhfr transgene along with the G.O.I.  
Since the DG44-PP cell line has many attP copies in the genome, it is possible that the 
limiting factor in promoting many integration events is the number of available attB sites.  
To increase the number of attB substrates we added an origin of replication for polyoma 
virus to the pBE16 plasmid which yielded plasmid pBE16ori.  Concurrently, we 
developed a cell line that stably expresses the large-T antigen from polyoma virus driven 
by a CMV promoter (DG44-PPTA).  Only polyoma large-T antigen needs to be 
expressed to allow replication of polyoma DNA in mammalian cells.  Previous studies 
have shown that this system has successfully replicated an incoming plasmid about 10000 
fold relative to plasmid levels without the large-T antigen in another CHO cell host (La 
Bella and Ozer, 1985).  A schematic of our experiments is shown in Figure 9.   
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Figure 9 – Schematic of Replicating Plasmid Experiments.  The dhfr/G.O.I. bearing 
plasmid now contains a polyoma origin of replication (ori).  This DNA is transfected into 
DG44-PPTA cells which contain many attP sites and polyoma large T-antigen driven by 
a CMV promoter.  The large T-antigen (black octagon) will bind the ori causing 
replication of the dhfr/G.O.I. bearing plasmid which increases the attB substrate available 
for recombination into genomic attP sites. 
 
We found that this cell line has successfully integrated the large T-antigen gene using 
PCR and confirmation of the correct sized band on an agarose gel.  We also found that it 
is expressing its mRNA by performing RT-PCR and confirmation of the correct sized 
band compared to a negative control where the reverse transcription step was not 
performed.  We measured the amount of attB plasmid 48 hours after transfection into the 
DG44-PPTA cell line compared to the same transfection in our original DG44-PP cells 
that does not express large T-antigen.  Using a Hirt extraction (Ziegler et al., 2004) which 
isolates only circular plasmid DNA from cells we measured the amount of attB plasmid 
and its degree of replication using both a DpnI assay and real-time PCR.  The DpnI 
restriction endonuclease only cleaves methylated recognition sites, which are synthesized 
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during growth in bacteria, therefore the newly replicated plasmid will remain undigested.  
The result from this assay was inconclusive since there was a high background of 
genomic DNA when performing the Hirt extraction.  This made it difficult to visualize 
the digested and undigested plasmid on an agarose gel.  Using real-time PCR we 
determined there was twice as much pBE16ori 48 hours post transfection than the pBE16 
plasmid in a parallel transfection.  This difference is not likely to substantially increase 
recombination of a transgene into the many genomic attP sites.  It is possible that the 
cellular environment of our cells differs from the cell line used previously to obtain such 
a high degree of plasmid replication using this system.  Detailed figures pertaining to 




The major bottleneck in trying to achieve many integration events may be the efficacy of 
the φC31 enzyme.  Although we are currently using a vector which strongly expresses the 
enzyme in the cell, its binding and subsequent catalysis of recombination may be 
improved through generating mutant enzymes.  The first method we employed was 
creating a protein chimera of φC31 integrase attached to 2 zinc finger binding domains 
(ZFBDs) via various protein linkers.  Concurrently we developed vectors containing attP 
and attB sites flanked by zinc finger binding sequences with various size sequence 
spacers between the attP or attB site and the zinc finger binding sequence.  The goal was 
to rationally find the best combination of φC31 chimera and attP/attB sequences which 
promotes maximum recombination efficiency.  A schematic of this process from the 
Master’s thesis of Laurens Moore van Tienen is shown in Figure 10.   
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Figure 10 – Schematic of φC31 integrase/zinc finger chimera.  AttP (dark blue) and 
attB (green) sites are flanked by variable spacer sequences and zinc finger binding sites.  
The φC31 integrase dimer (brown) is attached to a protein linker (black line) and a three 
finger zinc finger known as Zif268 (light blue) on either side.  Figure is from the 
Master’s thesis of Laurens Moore van Tienen.   
 
Testing these constructs in vivo was very time consuming due to the necessity to 
permanently transfect attP constructs, followed by the transfection of φC31 chimeras and 
attB constructs to assess colony formation by selecting for DHFR activity.  Due to this 
constraint we developed an in vitro assay which relies on transcription/translation (TnT) 
of the enzyme in vitro.  This involves transcribing and translating φC31 in solution and 
adding an attP and an attB construct to allow recombination to occur.  The degree of 
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recombination is then assessed by PCR using specific primers that only prime 




Figure 11 – In vitro Recombination Assay.  A kanamycin resistant plasmid 
(pPS6ex1GFP, blue) containing an attP site is mixed with an ampicillin resistant plasmid 
(pBS6ex2-6, green) containing an attB site.  The φC31 vector is also introduced to the 
mixture and transcribed and translated using an in vitro transcription/translation kit (TnT) 
to produce the enzyme (brown).  Successful recombination will result in the creation of a 
larger hybrid plasmid (pPS6ex1GFP-pBS6ex2-6 hybrid, blue and green).  Primer pairs A 
and D or B and C are used to create PCR products that will only be synthesized if 
recombination occurs.  Using primer A with B or C with D will result in a product with 
both original plasmids present.  The newly synthesized plasmid will confer resistance on 
agar plates supplemented with both kanamycin and ampicillin.  Figure is from the 
Master’s thesis of Laurens Moore van Tienen.   
 
Five different spacer lengths were tested ranging from 5 to 8 base pairs.  Nine different 
protein linkers were also tested of varying lengths and amino acid compositions.  Pure 
glycine linkers of lengths 4, 7, 11, 13, and 16 were tested along with 10 amino acid 
linkers of alternating serine and glyine, or serine and arginine.  A 10 amino acid linker of 
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only arginine was also tested along with a linker known as L6 which was previously 
shown to improve site-specific recombination.  All of these perturbations were tested to 
ensure that a wide range of lengths and linker flexibilities were assessed.  Of all the 
combinations of spacer lengths and linkers tested, only one gave a significant 
improvement in recombination efficiency.  The spacer length of 5 base pairs showed the 
most improvement in recombination regardless of whether the wild-type integrase or an 
integrase linked to a ZFBD was used.  The major result from this part of the work was 
that despite the presence of different ZFBDs and zinc finger binding sequences with 
various linkers and spacers, one spacer sequence on both sides of the attP and attB was 
the best option.  This spacer sequence improved φC31 recombination 23 fold over the 
wild-type attP and attB sequences we used in previous experiments using the in vitro 
assay.  Notably, this result was also seen using an in vivo assay which showed this 
improvement even with wild-type φC31 without ZFBDs.  This assay involved 
recombining an attB bearing plasmid with this specific spacer sequence flanking either 
end into a similar genomic attP site with the same flanks in the genome of CHO cells.  
Successful recombination was assayed be counting surviving colonies in PTF medium 
since the dhfr gene was reconstituted upon recombination.  This is indicative that 
sequence context alone surrounding the attP and attB sites can greatly affect 
recombination efficiency both in vivo and in vitro.  Interestingly, this 5 base pair long 
spacer contained a G on the 5’ side of the attP and attB site and a C on the 3’ side.  This 
corresponds to what naturally flanks the original attP site in phage phiC31.  The bacterial 
attB site has a G as the 5’ flank as well.  Perhaps the minimal 34bp and 39bp attB and 
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attP sequences previously determined are far from optimal for recombination (Groth et al., 
2000) 
A second method for improving φC31 integrase is using directed evolution.  We 
developed a method that allows for the generation of a large mutant φC31 library and 
several iterations of selecting improved mutants by linking genotype to phenotype.  Each 
mutant is kept separate from the other by using in vitro compartmentalization in a 
water/oil emulsion (Ghadessy and Holliger, 2004).  The details of this method are 
outlined in the Master’s thesis of Laurens Moore van Tienen.  Figure 12 shows a 
schematic of this process.  This process has not been yet implemented for our purposes 
but our future plans include using this method for isolating mutant φC31 integrases with 






Figure 12 – In vitro compartmentalization (IVC) Process for Isolating Efficient 
φC31 enzymes.  Step 1:  Error-prone PCR is used to generate many mutants of φC31.  
Each mutant is introduced into its own micro-droplet created from an oil/water emulsion 
at a limiting amount.  Step 2:  Each mutant is transcribed and translated into φC31 
enzyme.  Step 3:  Each mutant enzyme performs recombination on the introduced attP 
and attB substrates to form products containing attL and attR.  Step 4:  PCR is performed 
in the emulsion and is successful to the degree at which attL product is formed since this 
product is used as a primer.  Step 5:  The emulsion is broken and successful mutants will 
have had their phenotype of efficient recombination linked back to its genotype to be 
recovered by PCR and passed onto another iteration of the process.  Figure is from the 
Master’s thesis of Laurens Moore van Tienen.   
 
Discussion 
Our overall goal was integrating a transgene into our CHO host into as many locations as 
possible in one single transfection in order to abrogate the need for MTX amplification.  
The methods we employed to achieve this goal utilized site-specific recombination to 
target transgenes to many pre-established locations in the host genome.  The φC31 
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recombination system proved to be superior for this purpose due to its irreversibility for 
the integration reaction.  The three parameters we increased were increasing the number 
of attP sites in the genome through dCF gene amplification/ligation of attP concatemers, 
increasing the number of attB/G.O.I. incoming plasmids through viral replication, and 
improving the action of the φC31 integrase through modifying both the protein and the 
attP/attB binding sequences.   
Despite successfully isolating cell line DG44-PP containing over 7000 attP sites for 
potential targeting of a transgene, we were only able to achieve a 5 fold improvement 
over using random transfection of the same plasmid (pBE16) under the same conditions 
for an approximate copy number of 25.  This may speed up development of high copy 
number cell lines by allowing one to skip the first 2 steps (10nM and 20nM) of MTX 
amplification since cells will grow with up to 25 copies after a single transfection step.  
This is still a very modest increase and several more rounds of MTX amplification would 
be needed.  Increasing attP sites alone increases the probability of isolating clones 
resistant to 20nM, however it does not allow for isolation of a very high copy number 
(several hundred) clone resistant to the high levels of MTX.  It is possible that by 
performing a large enough transfection, one may isolate such a clone.   
Based on this result we concluded that at this point another bottleneck had been created 
either in the amount of available incoming dhfr/G.O.I. plasmid or the efficacy of the 
φC31 integrase.   
When we attempted to mimic previous work (La Bella and Ozer, 1985) that used viral 
replication to increase the amount of incoming plasmid 10000 fold we saw a negligible 
increase in our system.  As mentioned earlier, perhaps there are proteins in our host cell 
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that inhibit the action of the large T-antigen for binding to its origin of replication on our 
plasmid.  Another possible reason for this negligible increase is that other proteins are 
competing for this binding sequence on the plasmid hindering its replication.  It is also 
possible that the expressed large T-antigen is degraded before it is able to perform its 
function.  Adding mRNA stabilizing elements to its DNA sequence may show 
improvement.   
Our results shown in Table 1 indicate that calcium phosphate DNA co-precipitation is a 
superior transfection method over Lipofectamine 2000.  This may be due to its ability to 
physically deliver more dhfr/G.O.I. plasmid into the nucleus for recombination, or 
because it protects the φC31 DNA from degradation allowing it to be expressed.  Future 
work may be done to modify the timing of the delivery of both the φC31 plasmid and the 
dhfr/G.O.I. plasmid into host cells.  For example, it is possible that φC31 needs more 
time to be expressed before introduction of the dhfr/G.O.I. plasmid.  Perhaps transfection 
of φC31 first, followed by introduction of the dhfr/G.O.I. at later various times may 
improve recombination into more genomic attP sites.   
The φC31 enzyme has been shown to be inefficient in various other cell lines (Keravala 
et al., 2006; Thyagarajan et al., 2001b).  At this point it became clear we should focus our 
attention to modifying the enzyme itself to improve recombination efficiency.  This is the 
most likely bottleneck at this point in integrating transgenes into a large number of 
genomic recombination sites.  Work done by Laurens Moore van Tienen (Master’s 
student) showed that including a specific sequence flanking the attP and attB site could 
drastically improve recombination.  This leads us to continue investigating this 
phenomenon by using a high-throughput method of isolating attP/attB flanking sequences 
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that promote very efficient recombination.  We plan to develop a high throughput in vitro 
recombination assay for this purpose.  One plan is to test all random 5-mers flanking the 
attP and attB sequences for efficient recombination.  This process is described in more 
detail in Chapter 6.  Other options include generating a mutant library of 5’ and 3’ flanks 
of the original attP and attB site described by Calos et. al. on two separate DNA 
molecules.  We can then use high-throughput sequencing to identify mutant flanks that 
promote recombination.  Another option is to use SELEX (Systematic Evolution of 
Ligands by Exponential Enrichment).  This would use PCR to reproduce efficiently 
recombined sequences to enrich the subsequent population for further testing.  This may 
be iterated for several rounds before we isolate molecules that promote high levels of 
recombinations.  These experiments may ultimately lead to a small number of flank 
sequences that greatly improve recombination efficiency. 
Our work has modestly alleviated the time bottleneck associated with isolating high gene 
copy number cell lines coding for a specific therapeutically or diagnostically important 
protein.  We achieved a modest improvement in gene copy number isolated from a single 
transfection through the use of the φC31 recombination system and increasing its 
recognition substrates (attP and attB).  This result achieved led us to pursue modification 
of the φC31 enzyme which ultimately resulted in the discovery that attP and attB 
sequence context is important for recombination efficiency.  This work has paved the 
way for our future endeavor to isolate attP and attB flanking sequences that greatly 
improve this process.  This may ultimately allow a very high number of transgenes to be 
integrated into our host cells in one single transfection protocol, thus further alleviating 
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It is evident that biologics and in particular Mab’s have contributed significantly to 
treating various types of diseases.  Our overall goal was to improve the process of 
isolating high producing Mab cell lines by either decreasing the time needed to amplify 
the Mab gene to many copies, or integrating many copies of a Mab gene in one step.   
 
We have isolated a CHO clone which is capable of fast, reliable, and reproducible 
transgene amplification.  This was shown to be an improvement over random integration 
of a transgene followed by gene amplification.  This cell line can be utilized to direct any 
transgene of choice (i.e. for a Mab) for fast, reliable gene amplification.  We have also 
successfully developed a method using fluctuation analysis which can measure gene 
amplification rates in any host cell being used for recombinant protein production.  The 
method of measuring amplification rates of several clones carrying a φC31 SSR site may 
prove valuable in the isolation of a potential production host.  Despite the initial time 
investment of this process, it may save a considerable amount of development time once 
a highly amplifiable clone is isolated.   
 
In an effort towards removing the need to go through lengthy gene amplification we 
isolated a potential host CHO clone containing over 7000 copies of the φC31 SSR 
recognition sequence (attP sites) in the genome for potential integration of many copies 
of a transgene.  Despite the isolation of this clone, we were only able to successfully 
integrate 25 copies of a transgene into these sites, indicative that there is another 
bottleneck hindering many genomic integration events occurring.  This result led us to 
modifying both the φC31 enzyme and the recognition sites in which it initially binds to 
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improve genomic transgene integration.  We discovered that mutating the flanking DNA 
sequence around the φC31 recognition sites improved recombination considerably using 
both an in vitro and in vivo assay.   
 
Based on our last result we plan to conduct experiments which will select sequences 
flanking both the attP and attB upstream and downstream that promote the most efficient 
site-specific recombination.  Isolation of mutant flanking sequences and incorporating 
them in CHO host cell lines may alleviate this recombination bottleneck and allow more 
transgene copies to be integrated into many genomic sites.  We intend to perform this 
experiment by using an in vitro assay which can assess how well φC31 recombination 
occurs between two molecules (one with an attP site and one with an attB site).  Our first 
step will be to create two libraries of molecules.  The first library will be circular DNA 
molecules containing the standard wild-type φC31 attB site flanked by all single base pair 
substitutions (SBS) for the 5 base pairs on either side of the this sequence.  The second 
library will be linear DNA molecules containing the wild-type φC31 attP site flanked by 
SBS for the 5 base pairs on either side of this sequence.   These molecules will be mixed 
and incubated with recombinant φC31 recombinase produced in E. coli or by in vitro 
transcription and translation. Successful recombination of one circular attB containing 
molecule and one linear attP containing molecule will result in a longer linear molecule 
containing an attL sequence (upstream portion of attP site and downstream portion of 
attB site), and an attR sequence (upstream portion of attB site and downstream portion of 
attP site).  These recombination products will be isolated by gel electrophoresis on the 
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basis of their size. We will use high-throughput sequencing to determine which mutant 
flank combinations gave rise to the most recombinations using specific primers.   
We may iterate this process by testing flanking sequence beyond 5 base pairs depending 
on the obtained results. 
Mutant flank combinations which are present in high amounts will then be tested in vivo 
in our CHO host to determine if recombination of a transgene into many genomic 
locations is improved.  The best flank sequences for the attP site can be stably transfected 
into host CHO cells and amplified to many copies similar to the procedure described in 
chapter 5.  The best flank sequences for the attB site can then be co-transfected with the 
φC31 vector and recombination into many attP sites can be assessed. 
 
We have addressed the issue of the long development time associated with isolating high 
producing CHO clones for recombinant protein production.  First, we have isolated a 
clone with the capability of integrating any transgene for a therapeutic protein at a 
location prone to fast gene amplification.  This gives users the ability to isolate a high 
gene copy number clone in less time than they would if using the standard method of 
random transfection followed by gene amplification.  Users may also utilize our method 
of measuring gene amplification rates for other mammalian cell hosts by implementing 
fluctuation analysis.  This would allow for the isolation of any host capable of fast gene 
amplification.  Future experiments we propose have the potential to improve our system 
by removing the need for any gene amplification.  Upon isolation of attP and attB flank 
mutants and implementing them in a CHO host with thousands of sites for recombination, 
we may even further reduce development time of obtaining high producing clones for end 
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users.  The result of this work, coupled with other developments made in the field of 
biopharmaceutical development have the ability to continue to decrease the time needed 
to get biologic drugs to market. 
 
 
